<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544"><gtr:id>B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544</gtr:id><gtr:name>Bio.logis Genetic Information Management GMBH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9BB4EF0-4405-4A96-A361-289BB1928078"><gtr:id>B9BB4EF0-4405-4A96-A361-289BB1928078</gtr:id><gtr:name>University of Ljubljana</gtr:name><gtr:address><gtr:line1>University of Ljubljana</gtr:line1><gtr:line4>Ljubljana</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Slovenia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DEE9344-B2E6-458C-B226-C421D52A62DF"><gtr:id>3DEE9344-B2E6-458C-B226-C421D52A62DF</gtr:id><gtr:name>Diabetes UK</gtr:name><gtr:address><gtr:line1>10 Parkway</gtr:line1><gtr:line2>Campden</gtr:line2><gtr:postCode>NW1 7AA</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67"><gtr:id>0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67</gtr:id><gtr:name>The Federal Institute for Drugs and Medical Devices</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25F727A8-D64A-43E0-8AA9-4CF7BC2E18D1"><gtr:id>25F727A8-D64A-43E0-8AA9-4CF7BC2E18D1</gtr:id><gtr:name>MC Diagnostics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/990FEC22-C988-4943-AA62-01322D61942A"><gtr:id>990FEC22-C988-4943-AA62-01322D61942A</gtr:id><gtr:name>Medicines for Malaria Venture (MMV)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDDF2269-9D63-4717-A4C9-18DB51704DF6"><gtr:id>DDDF2269-9D63-4717-A4C9-18DB51704DF6</gtr:id><gtr:name>Otsuka Pharmaceutical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3390CFDA-74ED-431D-8048-FE87E6E0D8C9"><gtr:id>3390CFDA-74ED-431D-8048-FE87E6E0D8C9</gtr:id><gtr:name>Liverpool Heart and Chest Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF96472C-C9CC-4D84-A2E5-C304A7501580"><gtr:id>EF96472C-C9CC-4D84-A2E5-C304A7501580</gtr:id><gtr:name>Robert Bosch Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DC78695-EE95-4528-8ACC-E01C3B06B605"><gtr:id>9DC78695-EE95-4528-8ACC-E01C3B06B605</gtr:id><gtr:name>KNMP Holding B.V.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/07944F9A-421D-404B-BC16-79687AE5C68B"><gtr:id>07944F9A-421D-404B-BC16-79687AE5C68B</gtr:id><gtr:name>Liverpool Health Partners</gtr:name><gtr:address><gtr:line1>University of Liverpool</gtr:line1><gtr:line2>2nd Floor, Foundation Building</gtr:line2><gtr:line3>Brownlow Hill</gtr:line3><gtr:postCode>L69 7ZX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EE899202-565F-43EB-B462-A98C6C72EC5A"><gtr:id>EE899202-565F-43EB-B462-A98C6C72EC5A</gtr:id><gtr:name>Oncological Referral Centre (Centro di Riferimento Oncologico)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31A74B90-3EBC-45FC-83E2-515B95245315"><gtr:id>31A74B90-3EBC-45FC-83E2-515B95245315</gtr:id><gtr:name>Sengenics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A29EEAB3-451F-45E8-AB3C-BA6FDE7655E0"><gtr:id>A29EEAB3-451F-45E8-AB3C-BA6FDE7655E0</gtr:id><gtr:name>ASLAN Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/231A826B-DDAF-48DF-A388-9BB8AD1FB653"><gtr:id>231A826B-DDAF-48DF-A388-9BB8AD1FB653</gtr:id><gtr:name>University of Toulouse III Paul Sabatier</gtr:name><gtr:address><gtr:line1>UMR 5215</gtr:line1><gtr:line2>University Paul Sabatier</gtr:line2><gtr:line3>177, Avenue de Rangueil</gtr:line3><gtr:postCode>31077</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C2B8E0A-1A1C-4001-AF06-BE1A7B4A21F1"><gtr:id>9C2B8E0A-1A1C-4001-AF06-BE1A7B4A21F1</gtr:id><gtr:name>Academy of Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4822D555-BD0C-4560-9E9B-4FA59A8ECD57"><gtr:id>4822D555-BD0C-4560-9E9B-4FA59A8ECD57</gtr:id><gtr:name>St Antonius Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AC141207-8DF3-421F-A604-1500E71BAF1C"><gtr:id>AC141207-8DF3-421F-A604-1500E71BAF1C</gtr:id><gtr:name>The Golden Helix Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/269A674D-C5F9-42B2-90FA-D3563D3FA8BF"><gtr:id>269A674D-C5F9-42B2-90FA-D3563D3FA8BF</gtr:id><gtr:name>Sysmex Corporation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13DABD91-2872-4018-B377-DD813F21C894"><gtr:id>13DABD91-2872-4018-B377-DD813F21C894</gtr:id><gtr:name>University of Patras</gtr:name><gtr:address><gtr:line1>Rion-Patras</gtr:line1><gtr:postCode>GR - 265-0</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Greece</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/276CCBAB-1433-4E39-BEA5-E8327D170815"><gtr:id>276CCBAB-1433-4E39-BEA5-E8327D170815</gtr:id><gtr:name>Servicio C?ntabro de Salud</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Institute of Translational Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544"><gtr:id>B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544</gtr:id><gtr:name>Bio.logis Genetic Information Management GMBH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9BB4EF0-4405-4A96-A361-289BB1928078"><gtr:id>B9BB4EF0-4405-4A96-A361-289BB1928078</gtr:id><gtr:name>University of Ljubljana</gtr:name><gtr:address><gtr:line1>University of Ljubljana</gtr:line1><gtr:line4>Ljubljana</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Slovenia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DEE9344-B2E6-458C-B226-C421D52A62DF"><gtr:id>3DEE9344-B2E6-458C-B226-C421D52A62DF</gtr:id><gtr:name>Diabetes UK</gtr:name><gtr:address><gtr:line1>10 Parkway</gtr:line1><gtr:line2>Campden</gtr:line2><gtr:postCode>NW1 7AA</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67"><gtr:id>0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67</gtr:id><gtr:name>The Federal Institute for Drugs and Medical Devices</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25F727A8-D64A-43E0-8AA9-4CF7BC2E18D1"><gtr:id>25F727A8-D64A-43E0-8AA9-4CF7BC2E18D1</gtr:id><gtr:name>MC Diagnostics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/990FEC22-C988-4943-AA62-01322D61942A"><gtr:id>990FEC22-C988-4943-AA62-01322D61942A</gtr:id><gtr:name>Medicines for Malaria Venture (MMV)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDDF2269-9D63-4717-A4C9-18DB51704DF6"><gtr:id>DDDF2269-9D63-4717-A4C9-18DB51704DF6</gtr:id><gtr:name>Otsuka Pharmaceutical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3390CFDA-74ED-431D-8048-FE87E6E0D8C9"><gtr:id>3390CFDA-74ED-431D-8048-FE87E6E0D8C9</gtr:id><gtr:name>Liverpool Heart and Chest Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF96472C-C9CC-4D84-A2E5-C304A7501580"><gtr:id>EF96472C-C9CC-4D84-A2E5-C304A7501580</gtr:id><gtr:name>Robert Bosch Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DC78695-EE95-4528-8ACC-E01C3B06B605"><gtr:id>9DC78695-EE95-4528-8ACC-E01C3B06B605</gtr:id><gtr:name>KNMP Holding B.V.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07944F9A-421D-404B-BC16-79687AE5C68B"><gtr:id>07944F9A-421D-404B-BC16-79687AE5C68B</gtr:id><gtr:name>Liverpool Health Partners</gtr:name><gtr:address><gtr:line1>University of Liverpool</gtr:line1><gtr:line2>2nd Floor, Foundation Building</gtr:line2><gtr:line3>Brownlow Hill</gtr:line3><gtr:postCode>L69 7ZX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE899202-565F-43EB-B462-A98C6C72EC5A"><gtr:id>EE899202-565F-43EB-B462-A98C6C72EC5A</gtr:id><gtr:name>Oncological Referral Centre (Centro di Riferimento Oncologico)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31A74B90-3EBC-45FC-83E2-515B95245315"><gtr:id>31A74B90-3EBC-45FC-83E2-515B95245315</gtr:id><gtr:name>Sengenics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A29EEAB3-451F-45E8-AB3C-BA6FDE7655E0"><gtr:id>A29EEAB3-451F-45E8-AB3C-BA6FDE7655E0</gtr:id><gtr:name>ASLAN Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/231A826B-DDAF-48DF-A388-9BB8AD1FB653"><gtr:id>231A826B-DDAF-48DF-A388-9BB8AD1FB653</gtr:id><gtr:name>University of Toulouse III Paul Sabatier</gtr:name><gtr:address><gtr:line1>UMR 5215</gtr:line1><gtr:line2>University Paul Sabatier</gtr:line2><gtr:line3>177, Avenue de Rangueil</gtr:line3><gtr:postCode>31077</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C2B8E0A-1A1C-4001-AF06-BE1A7B4A21F1"><gtr:id>9C2B8E0A-1A1C-4001-AF06-BE1A7B4A21F1</gtr:id><gtr:name>Academy of Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4822D555-BD0C-4560-9E9B-4FA59A8ECD57"><gtr:id>4822D555-BD0C-4560-9E9B-4FA59A8ECD57</gtr:id><gtr:name>St Antonius Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC141207-8DF3-421F-A604-1500E71BAF1C"><gtr:id>AC141207-8DF3-421F-A604-1500E71BAF1C</gtr:id><gtr:name>The Golden Helix Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/269A674D-C5F9-42B2-90FA-D3563D3FA8BF"><gtr:id>269A674D-C5F9-42B2-90FA-D3563D3FA8BF</gtr:id><gtr:name>Sysmex Corporation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13DABD91-2872-4018-B377-DD813F21C894"><gtr:id>13DABD91-2872-4018-B377-DD813F21C894</gtr:id><gtr:name>University of Patras</gtr:name><gtr:address><gtr:line1>Rion-Patras</gtr:line1><gtr:postCode>GR - 265-0</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Greece</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/276CCBAB-1433-4E39-BEA5-E8327D170815"><gtr:id>276CCBAB-1433-4E39-BEA5-E8327D170815</gtr:id><gtr:name>Servicio C?ntabro de Salud</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/71087E01-D085-4094-80C8-484FCF5B21D1"><gtr:id>71087E01-D085-4094-80C8-484FCF5B21D1</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Park</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL006758%2F1"><gtr:id>D9BF8733-68BA-44C8-BA0B-542AD45A0CFE</gtr:id><gtr:title>Centre for Drug Safety Science (CDSS)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L006758/1</gtr:grantReference><gtr:abstractText>The use of drugs as medicines has made an enormous contribution to human health with the drug discovery process being directed to most aspects of human disease. However, all drugs are associated with side effects or adverse drug reactions (ADRs) which vary in frequency and severity dependent on the drug and patient population. The overall burden is large to both the NHS and Industry.

We have shown that at least 6.5% of all adult admissions to hospitals are due to ADRs and that approximately 15% of inpatients suffer an ADR during hospitalisation. Extrapolated nationally, ADRs are thought to cost the NHS in England in excess of &amp;pound;637 million annually, or approximately &amp;pound;5000 per hospital bed per year. This is a conservative estimate and is likely to be much higher. Our findings in the UK have been replicated in many countries showing that ADRs are a global health issue.

ADRs can lead to withdrawal or restricted use of drugs, even if the ADR occurs in only a minority of patients. This can impede the use of otherwise effective drugs being prescribed by physicians for the majority of patients who benefit from the drug without developing ADRs. The whole issue of drug safety also has a major impact on the profitability of the pharmaceutical industry, and thus the economy of the UK.

The MRC Centre for Drug Safety Science (CDSS) was therefore created in 2008 as a collaboration between the Universities of Liverpool (UoL) and Manchester (UoM) in response to a perceived need to establish a National Centre to investigate mechanisms of ADRs. 

An infrastructure that allows pre-clinical and clinical scientists to work side-by-side using cutting-edge technologies to analyse well-defined clinical samples has been created in CDSS. Progress has been made in our understanding of the mechanisms of drug-induced liver injury and drug-induced hypersensitivity, including the identification of genetic predisposing factors and the development of improved diagnostic tests. Over the next 5 yrs our innovative findings will be translated into better clinical care for patients, improved drug development for Pharmaceutical Industry and better information for Regulators. Furthermore, our infrastructure will be extended to evaluate drug side effects associated with the kidney, the gastrointestinal tract and the cardiovascular system. Collectively, the findings from the CDSS and its collaborators will provide a better understanding of risk of ADRs and improve patient outcomes. 

We will continue to work closely with scientists from the pharmaceutical industry and from regulatory authorities in a non-competitive manner that will allow us to access company-specific drugs and patient samples which provide us with the tools to address industry-wide drug safety challenges. At the same time we will act as a forum for training and knowledge exchange with all drug safety science professionals (be they in academia, health care providers, industry or regulatory authorities) which will be significantly enhanced by our expanded training programme for non-clinical and clinical scientists. This will allow us to improve capacity in drug safety science in the UK for all relevant stakeholders. We will continue our patient and public engagement activities at all levels in order to ensure that our aims and objectives are refined to make patients a central focus of the research and training activities in the Centre.

Thus the new mission statement for the Centre is &amp;quot;to use the critical mass and knowledge in drug safety science that we have now accrued within the Centre to undertake leading edge science, and train the next generation of drug safety scientists, to understand the fundamental mechanisms of clinically important and currently relevant adverse drug reactions in order to develop strategies to improve the benefit-risk ratio of current and new medicines, for the benefit of patients, industry and regulators.&amp;quot;</gtr:abstractText><gtr:technicalSummary>Adverse drug reactions (ADRs) are a major public health problem. The Centre for Drug Safety Science (CDSS) has developed an integrated chemical, biochemical, molecular, cellular and genetic approach to analyse the fundamental and complex mechanisms of ADRs in both in vitro and in vivo models. We have a matrix approach for the: a) collection and biobanking of clinical material; b) construction of experimental methods with appropriate statistical and informatic modelling and c) application of state of the art qualitative and quantitative bioanalytical methodologies in order to be able to define the chemical, biological and genetic basis of clinically-relevant ADRs. This allows us to address each specific issue in a fundamental manner, but also to operate with efficiency and effectiveness in the CDSS across both established and newly emerging safety issues. 
The CDSS provides critical mass for bioanalysis in terms of equipment and specialised personnel for both the execution of research and for training the next generation of drug safety scientists (clinical and non-clinical). We have a truly inter-disciplinary environment within CDSS with pharmacologists, chemists, cell biologists, molecular biologists, geneticists, computational biologists, mathematicians, modellers, immunologists and clinicians working side-by-side with the aim of taking our findings from the bench to the bedside to application, and also in the reverse direction. 
Collaboration is critical for the maintenance of the technical capability of the CDSS. Thus we work closely with industry scientists and regulators, to develop and apply new scientific methods that become fit for purpose with respect to hazard identification and risk analysis for both established and new classes of therapeutic agents.
The comprehensive approach adopted by the CDSS is designed to reduce the burden of ADRs for both patients and for Industry, thus achieving the dual aims of improving patient health and creating wealth.</gtr:technicalSummary><gtr:potentialImpactText>The beneficiaries from research in the Centre for Drug Safety Science are:
1. Academia
- Publishing our research in high-impact journals will ensure that the science-base grows in the physiological, pharmacological and toxicological responses to medicines
- As an international centre of excellence for drug safety science we will continue to bring together diverse groups of experts in order to enhance our specific research programmes. This will particularly relate to researchers who have previously had no experience in the drug safety science field.
- Other national and international academic groups that are working on specific aspects of drug safety science will gain from collaborative links with CDSS, either from access to our clinical samples, access to our cross-cutting technologies, or access to our intellectual expertise.
- The strong training element of the CDSS will ensure that non-clinical and clinical academic capacity in drug safety science is enhanced. The comprehensive training in highly integrated projects involving state-of-the-art academic fields from pharmacology through to medicinal chemistry will produce 'rounded' scientists with sought-after skill-sets who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK.
2. Health Service providers
- Knowledge gained from the CDSS will lead to changes to drug labels and more effective prescribing
- Data produced by the CDSS will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies
- Scientific outputs from the Centre will ultimately reduce ADR frequency and their associated financial burden
- Continued training will increase the capacity in Clinical Pharmacology and Therapeutics
- The novelty in design of clinical studies, with patient input where appropriate, will provide the framework for further studies worldwide to replicate and advance the findings from CDSS.
3. Pharmaceutical Industry
- Scientists from the pharmaceutical industry will continue to use the CDSS as a focal point for non-competitive research
- The CDSS will continue to develop and run workshops on issues of importance to the pharmaceutical industry by bringing together appropriate experts from industry and the academic sector that will build new collaborations (not necessarily with Centre scientists) and drive novel scientific plans.
- The CDSS will allow industry scientists to spend sabbatical time in an academic setting, improving both personal development and industry-academia interactions.
- Scientific outputs from the CDSS will be used to develop drugs with better benefit:risk profiles
4. Diagnostics Sector
- Advances in mechanistic understanding of ADRs will open up new opportunities for the development of diagnostic and prognostic testing strategies that can be commercialised by the diagnostics sector leading to an improvement in the benefit:risk of drugs
5.Regulatory Authorities
- Regulatory scientists will input into and gain benefit from the CDSS workshops
- CDSS scientists will continue to provide expertise to various advisory committees of the MHRA and EMA.
- Scientific outputs from the CDSS enhance the ability of drug regulators to include the relevant information in drug labels. This will thereby contribute towards better evidence-based policy making at a global level.
6.Patients and the General Public
- By feeding knowledge and scientific advances through to other stakeholder groups, we will ultimately reduce the incidence of ADRs and allow for the pharmaceutical industry to develop safer drugs. These improvements will clearly have a major impact on enhancement of the clinical care of patients thereby leading to an improvement in quality of life.
- The general public retains a significant interest in drug safety and the CDSS will educate the public in their perception of risks associated with medicines.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2453540</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Novartis (MRC Fellowship)</gtr:description><gtr:id>A034C164-93EE-422F-8E59-8210824A204F</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d5718f48f1c0.94644019-1</gtr:outcomeId><gtr:partnerContribution>Novartis will provide a nominated representative to sit on the scheme's programme management board to support the running and development of the scheme. The representative will take part in decision making processes to appoint Fellows.
Novartis will provide &amp;pound;300K cash contribution to the Scheme over 4 years and will, in addition, provide &amp;pound;60K in-kind contribution reflecting the time given to the Scheme by the nominated representative and PhD co-supervisors.
Novartis will support the identification and development of potential projects with individual Fellowship candidates. Should the candidate(s) be successful, they will be assigned an industry co-supervisor who will provide regular input into their project. Importantly, projects will be developed such that a prolonged secondment at Novartis is built into the project plans. The secondment will allow the Fellow to access technologies and expertise that may not be available in the academic institutions and/or it will allow the fellow to work on specific aspects of their research which will contribute to the quality of the thesis. The partnership with Industry will provide individual Fellows with first-hand experience of how the pharmaceutical industry operates.</gtr:partnerContribution><gtr:piContribution>The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of &amp;gt;1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CyTof procurement</gtr:description><gtr:id>5D16812D-38B4-47AD-AD73-4DAD90C655C7</gtr:id><gtr:impact>Favourable cost reductions for all partners during procurement of seven individual CyTOF machines.</gtr:impact><gtr:outcomeId>56dffbe1030ec0.26607735-3</gtr:outcomeId><gtr:partnerContribution>Supporting Professor Beynon where necessary and appropriate</gtr:partnerContribution><gtr:piContribution>Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards
user-group network meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Roche (MRC Fellowship)</gtr:description><gtr:id>CE378DDA-B3E0-44EA-B654-456C1B0DC712</gtr:id><gtr:impact>None Yet</gtr:impact><gtr:outcomeId>56d5750c5a7b76.76684205-1</gtr:outcomeId><gtr:partnerContribution>Roche will provide a nominated representative to sit on the scheme's programme management board to support the running and development of the scheme. The representative will take part in decision making processes to appoint Fellows.
Roche will provide &amp;pound;300K cash contribution to the Scheme over 4 years and will, in addition, provide &amp;pound;60K in-kind contribution reflecting the time given to the Scheme by the nominated representative and PhD co-supervisors.
It is anticipated that any projects developed in collaboration with Roche will focus on enabling science around a methodology or platform that can provide insights into an already approved [company name] product, or in understanding the mechanisms of disease and improving the benefit-risk ratio of drugs. This will produce valuable generalised publishable information of use to the scientific community as a whole.</gtr:partnerContribution><gtr:piContribution>The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of &amp;gt;1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Eli Lilly (MRC Fellowship)</gtr:description><gtr:id>ED6C1792-271D-4A46-A944-4A38711D50C0</gtr:id><gtr:impact>None Yet</gtr:impact><gtr:outcomeId>56d5742fd38aa5.50430963-1</gtr:outcomeId><gtr:partnerContribution>As and industry partner, Lilly may provide a nominated representative to sit on the Scheme's programme management board to support the running and development of the scheme. The representative may take part in decision making processes to appoint Fellows.
Lilly may provide &amp;pound;300K cash contribution to the Scheme over 4 years and may, in addition, provide in-kind contribution reflecting the time and facilities given to the Scheme by the industry partner.
It is anticipated that any projects developed in collaboration with Lilly will focus on enabling science around a methodology or platform that can provide insights into an already approved product, or in understanding the mechanisms of disease and improving the benefit-risk ratio of drugs. This should produce valuable generalised publishable information of use to the scientific community as a whole.</gtr:partnerContribution><gtr:piContribution>The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of &amp;gt;1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pfizer research project - bosutinib</gtr:description><gtr:id>16EC4A32-AE9B-4508-9B7D-0D692E2BE82E</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>54623469e908a8.48088179-1</gtr:outcomeId><gtr:partnerContribution>Scientific collaboration and oversight of project deliverables and milestones</gtr:partnerContribution><gtr:piContribution>An investigation into the use of ex-vivo rodent and human hepatocyte models to study bosutinib-induced liver toxicity</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB Pharma (MRC Fellowship)</gtr:description><gtr:id>3B2CCAAF-2BAC-4783-948F-573B562E06E6</gtr:id><gtr:impact>None Yet</gtr:impact><gtr:outcomeId>56d5724f511016.55777807-1</gtr:outcomeId><gtr:partnerContribution>UCB Celltech will provide a nominated representative to sit on the scheme's programme management board to support the running and development of the scheme. The representative will take part in decision making processes to appoint Fellows.
UCB Celltech will provide &amp;pound;300K cash contribution to the Scheme over 4 years and will, in addition, provide &amp;pound;60K in-kind contribution reflecting the time given to the Scheme by the nominated representative and PhD co-supervisors.
It is anticipated that any projects developed in collaboration with UCB Celltech will focus on enabling science around a methodology or platform that can provide insights into an already approved UCB Celltech product, or in understanding the mechanisms of disease and improving the benefit-risk ratio of drugs. This will produce valuable generalised publishable information of use to the scientific community as a whole.</gtr:partnerContribution><gtr:piContribution>The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of &amp;gt;1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>PBMC responses to in vitro testing of AMG 747 and related glycine transporter type-1 (GlyT1) inhibitors</gtr:description><gtr:id>095EE7BB-3F1B-4DE6-812C-BFA773323996</gtr:id><gtr:impact>Drug-specific T cells were not detected</gtr:impact><gtr:outcomeId>56d59f82e455d0.80744046-1</gtr:outcomeId><gtr:partnerContribution>Provision of patient blood sample, drug and &amp;pound;6K cash contribution</gtr:partnerContribution><gtr:piContribution>Analysis of T-cell responses in a patient with Stevens Johnson Syndrome</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Antonius Hospital</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>St. Antonius Hospital Foundation</gtr:department><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>4A28E27E-26AB-475E-95D6-478D47E49DB0</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-7</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Patras</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>B2EC98CD-EE36-4E4B-983B-4D10791C1365</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-13</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oncological Referral Centre (Centro di Riferimento Oncologico)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>8283DD56-4BB1-41B4-A32D-408DA7F7C142</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-11</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CyTof procurement</gtr:description><gtr:id>028AB9BD-ADE0-4B55-ADAE-6C2D8A66CC0C</gtr:id><gtr:impact>Favourable cost reductions for all partners during procurement of seven individual CyTOF machines.</gtr:impact><gtr:outcomeId>56dffbe1030ec0.26607735-5</gtr:outcomeId><gtr:partnerContribution>Supporting Professor Beynon where necessary and appropriate</gtr:partnerContribution><gtr:piContribution>Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards
user-group network meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool Heart and Chest Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>INSTITUTE OF CARDIOVASCULAR MEDICINE AND SCIENCE (ICMS)</gtr:description><gtr:id>EF04B2D4-B31A-4870-ACB1-0DE74139882E</gtr:id><gtr:impact>ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University.</gtr:impact><gtr:outcomeId>56d6cc406436a9.35158019-1</gtr:outcomeId><gtr:partnerContribution>ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University.</gtr:partnerContribution><gtr:piContribution>University representative on the Executive Committee and Board</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MC Diagnostics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MC Diagnostics</gtr:description><gtr:id>DA58F87E-66A3-4C74-BE6E-95095DA65E1A</gtr:id><gtr:impact>Please see publications listed under the specific grant on research fish (it is linked to that award)</gtr:impact><gtr:outcomeId>ZPA7b9ghMzX-1</gtr:outcomeId><gtr:partnerContribution>Partnership with MC Diagnostics which has led to the award of an NIHR i4i grant (&amp;pound;350K)</gtr:partnerContribution><gtr:piContribution>Partnership with MC Diagnostics which has led to the award of an NIHR i4i grant (&amp;pound;350K).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Liverpool Clinical Research Unit (CRU)</gtr:department><gtr:description>Future Initiative</gtr:description><gtr:id>4AD36D73-F589-4D52-9067-F956E5F89F2F</gtr:id><gtr:impact>None Yet.</gtr:impact><gtr:outcomeId>56d56fbb484443.85840190-1</gtr:outcomeId><gtr:partnerContribution>The study population will be recruited through the Royal Liverpool &amp;amp; Broadgreen University Teaching Hospitals NHS Trust (RLBUHT). Some Phase 1 trials will be conducted at the Royal Liverpool Clinical Research Unit.</gtr:partnerContribution><gtr:piContribution>FUTURE will provide access to a stratified cohort of healthy volunteers for clinical trials who have been genotyped for drug metabolising enzyme and transporter genes that can be readily recruited for phase I healthy volunteer studies. Part 1 of FUTURE will focus on recruiting a prospective cohort of 3000 healthy volunteers. Part 2 of FUTURE will provide a business model whereby FUTURE will offer access to a panel of genotyped healthy volunteers for potential recruitment to phase I trials. The study population will be recruited through the Royal Liverpool &amp;amp; Broadgreen University Teaching Hospitals NHS Trust (RLBUHT). If necessary recruitment will open up to other research centres to assist reaching the recruitment target for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Servicio C?ntabro de Salud</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>DE850B04-1BF2-42A3-B933-E527871C27B9</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-12</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Diabetes UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Precision Medicine Catapult</gtr:department><gtr:description>The Precision Medicine Catapult.</gtr:description><gtr:id>26198023-E4F4-4D78-8CD8-AEBEDE44F160</gtr:id><gtr:impact>this partnership will significantly increases the impact of our network's activities. We expect this collaboration to be highly effective as we work together to develop the precision medicine solutions which are revolutionising healthcare.&amp;quot;</gtr:impact><gtr:outcomeId>56d6b0f9ea4320.83294723-1</gtr:outcomeId><gtr:partnerContribution>Ensuring better patient outcomes

Under the new partnership, the two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes.
The Precision Medicine Catapult, created in April 2015 by Innovate UK, brings access to unique programmes, collaborations, initiatives and expertise from its global connections. It is focused on making the UK the most compelling location in the world for the development and delivery of this new targeted approach</gtr:partnerContribution><gtr:piContribution>Under the new partnership, the two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Amgen project grant - Keap1 and hepatotoxicity</gtr:description><gtr:id>EFEA49B9-6CBD-42C5-8783-4A7D66218E21</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>54623582427ca7.57645270-1</gtr:outcomeId><gtr:partnerContribution>Scientific collaborators and oversight of project deliverables and milestones</gtr:partnerContribution><gtr:piContribution>Generation and Validation of Models to Probe Keap1 Adduction as a Marker of the Hepatotoxic Liability of Drug Candidates.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ASLAN Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>Liver biomarker analysis of ASLAN-003</gtr:description><gtr:id>4AD83B0F-5B43-4627-8587-DD60C4F7647C</gtr:id><gtr:impact>Data generated by CDSS supported the company in deciding to stop clinical development of ASLAN-003</gtr:impact><gtr:outcomeId>56d5a0c6651d70.43742439-1</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples and budget</gtr:partnerContribution><gtr:piContribution>Analysis of blood samples from a clinical study to support go/no go decision making process.
Samples were analysed for liver-injury-specific biomarkers</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bio.logis Genetic Information Management GMBH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>A5174CC5-980D-45CE-BA1C-3C02B7E51CFE</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-6</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ljubljana</gtr:collaboratingOrganisation><gtr:country>Slovenia, Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>40E8D8D4-1880-43DF-AC4A-CA2206E24516</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-14</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Naproxen idiosyncratic drug-induced liver injury</gtr:description><gtr:id>C9072F7B-5C14-4031-A19C-583A25C2B36B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d5a615481446.63248212-1</gtr:outcomeId><gtr:partnerContribution>Provision of drug material and finance; secondment of Novartis scientist to CDSS laboratories</gtr:partnerContribution><gtr:piContribution>Research project planning and hosting Novartis scientist in CDSS to perform research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Merck project grant - translational DILI biomarkers</gtr:description><gtr:id>CE5C14B4-078D-4802-94D4-9B165D8CFCF0</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>5462363a5a2ee6.46012850-1</gtr:outcomeId><gtr:partnerContribution>Scientific collaboration and oversight of milestones and deliverables</gtr:partnerContribution><gtr:piContribution>Scientific leadership; development of infrastructure to support clinical sample collection relevant to the project; laboratory activities.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Golden Helix Foundation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>0A7803DB-3C20-403E-A2D3-587DB6674427</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-4</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astex Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Analysis of novel serum mechanism-based biomarkers that have enhanced liver specificity for the detection of acute livery injury, cell death (apoptosis and necrosis) and inflammation.</gtr:description><gtr:id>4F6C04BD-B8F2-48AA-A99F-2E747E625195</gtr:id><gtr:impact>Data generated from CDSS has given the company a greater understanding of the benefit-risk balance for a drug candidate which has now moved forward to clinical testing</gtr:impact><gtr:outcomeId>56d5a281e6f401.14490596-1</gtr:outcomeId><gtr:partnerContribution>Provision of blood samples from NHP study and finance</gtr:partnerContribution><gtr:piContribution>DILI biomarker analysis from pre-clinical NHP toxicity study</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>867C2150-DA41-4072-8310-45B87E12F18A</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-3</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>923BB6B0-777F-4657-9633-A297F8A52215</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-10</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sysmex Corporation</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>New mechanistic extracellular matrix-derived biomarkers to predict the progression of liver fibrosis to cirrhosis</gtr:description><gtr:id>430BFCEF-C10D-41D1-B5F8-E0BEF0C8100A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d5a4f2859a45.67287911-1</gtr:outcomeId><gtr:partnerContribution>Financial</gtr:partnerContribution><gtr:piContribution>Identification of mechanistic biomarkers of liver fibrosis</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CyTof procurement</gtr:description><gtr:id>AB270787-CA8D-47A5-8E6A-D0890FE5AB46</gtr:id><gtr:impact>Favourable cost reductions for all partners during procurement of seven individual CyTOF machines.</gtr:impact><gtr:outcomeId>56dffbe1030ec0.26607735-2</gtr:outcomeId><gtr:partnerContribution>Supporting Professor Beynon where necessary and appropriate</gtr:partnerContribution><gtr:piContribution>Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards
user-group network meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Robert Bosch Foundation</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Robert Bosch Foundation for Medical Research (RBMF)</gtr:department><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>8239D702-C9A9-46B7-B56D-511EFDCF2E34</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-15</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>15CCAE86-5ED5-4798-A2DB-8E9FEAAF6978</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-1</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK collaboration - lapatinib project</gtr:description><gtr:id>BD3657FA-4E37-4675-8F95-7C8901CC1E31</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545cf70cdc07c9.38467379-1</gtr:outcomeId><gtr:partnerContribution>Collection of blood samples from five patients (and matched controls) with specific genotypes that developed liver injury, and provision of lapatinib and key metabolites (synthesised by GSK chemists)</gtr:partnerContribution><gtr:piContribution>Evaluation of immune mechanisms associated with lapatinib-induced liver toxicity</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CyTof procurement</gtr:description><gtr:id>207A83AC-BCD1-4805-9E03-FA07BFDA29BF</gtr:id><gtr:impact>Favourable cost reductions for all partners during procurement of seven individual CyTOF machines.</gtr:impact><gtr:outcomeId>56dffbe1030ec0.26607735-1</gtr:outcomeId><gtr:partnerContribution>Supporting Professor Beynon where necessary and appropriate</gtr:partnerContribution><gtr:piContribution>Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards
user-group network meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>3F2427AB-1233-4E24-B51E-17218A62CA48</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-8</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Otsuka Pharmaceutical</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Investigation of immunological mechanisms relating to tolvaptan-induced hepatotoxicity</gtr:description><gtr:id>51816970-A424-45F0-9399-2DA3FA71CC7C</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d5a591c1be11.11593855-1</gtr:outcomeId><gtr:partnerContribution>Provision of patient samples, drug material and finance</gtr:partnerContribution><gtr:piContribution>Mechanistic work to identify drug-specific T-cell responses in patient blood samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CyTof procurement</gtr:description><gtr:id>81446C1B-4BC6-4596-83EF-E23DD422064E</gtr:id><gtr:impact>Favourable cost reductions for all partners during procurement of seven individual CyTOF machines.</gtr:impact><gtr:outcomeId>56dffbe1030ec0.26607735-4</gtr:outcomeId><gtr:partnerContribution>Supporting Professor Beynon where necessary and appropriate</gtr:partnerContribution><gtr:piContribution>Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards
user-group network meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>INSTITUTE OF CARDIOVASCULAR MEDICINE AND SCIENCE (ICMS)</gtr:description><gtr:id>B58E520A-D671-435D-BE24-C7AEAB1AA782</gtr:id><gtr:impact>ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University.</gtr:impact><gtr:outcomeId>56d6cc406436a9.35158019-2</gtr:outcomeId><gtr:partnerContribution>ICMS has been a huge success particularly in terms of publications and PhDs; In circa almost 200 publications attributed to ICMS There have been about 10-12 PhDs, initially registered through Imperial College hopefully in the future registered through both Imperial College and Liverpool University.</gtr:partnerContribution><gtr:piContribution>University representative on the Executive Committee and Board</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KNMP Holding B.V.</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>D5CBB033-75BF-4651-827F-CB8C46FE346D</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-5</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academy of Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Academy of Finland - Grant review panel member, Feb 2017</gtr:description><gtr:id>4C25F444-63E2-4A84-B3FC-79B33E7CEBF9</gtr:id><gtr:impact>future collaboration in pharmaceutical research.</gtr:impact><gtr:outcomeId>58904d99c36692.73674975-1</gtr:outcomeId><gtr:partnerContribution>invitied to participate in of one of Finlands evaluation panels in February 2017. The panel, consisting of approximately nine experts, to evaluate applications in the field of pharmaceutical research. assisted in the contribution and the promotion of Finnish science by taking part in the work of this evaluation panel.

The panel that you are invited to will convene for a one-day meeting near the Academy of Finland, Helsinki, on Wednesday, 1st February 2017, 8:30am-16:00pm. Professor V&amp;eacute;ronique Pr&amp;eacute;at from Louvain Drug Research Institute, Belgium, will act as chair of the panel. Prior to the meeting, the panel members are asked to write draft statements of approximately 10 applications using online evaluation forms with preset criteria. These drafts (from two experts per application) form the working material for the panel during the meeting day. Panellists are also asked to read few additional applications for the meeting.

The schedule for the review process:
- The call for proposals expired at the end of September 2016. 
- You will have access to the applications through the Academy's online services by early December 2016.
- The draft evaluations will be submitted electronically. The deadline for submitting the draft statements will be two weeks before the meeting. All drafts will be made available to the panel members prior to the panel meeting. 
- The panel will meet on 1st February 2017 in Helsinki, Finland. 
- The final statements will be written during the meeting, with the help of science advisers from the Academy of Finland.</gtr:partnerContribution><gtr:piContribution>The Academy of Finland is the main public funding organization supporting basic research at universities and research institutes in Finland. Intense competition in our small country and wide national collaboration among researchers make it necessary and vital for us to use external international expertise for evaluation of grant applications.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Manchester (MRC Fellowship)</gtr:description><gtr:id>A9454525-D437-4516-924F-E83A17DF2E57</gtr:id><gtr:impact>None Yet</gtr:impact><gtr:outcomeId>56d575af43c1e9.75582230-1</gtr:outcomeId><gtr:partnerContribution>The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of &amp;gt;1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM.</gtr:partnerContribution><gtr:piContribution>The combination of 2 universities and 4 major Pharma partners will provide a unique environment for clinical pharmacology training for 13 Clinical Research Fellows, allowing integration of expertise and technologies across the M62 (Universities' of Liverpool and Manchester) and, with our four industry partners. Liverpool has the largest CPT training programme in the UK, where there is seamless working between clinical and basic pharmacologists. Combining this with Manchester's strengths in clinical translational research forms a powerful synergism. The trainees in this scheme will be able to join and interact with a critical mass of &amp;gt;1000 postgraduate students in both Universities, including clinical research Fellows (35 in Liverpool, 22 in Manchester) funded through a number of funders including MRC, Wellcome Trust and CR-UK. A unique environment has thus been created, and will be further enhanced through renewal which allows for (a) close working between clinical and non-clinical Fellows; (b) the complementary academic strengths of the 2 Universities; (c) well phenotyped patient cohorts; (d) bespoke training that complements and enhances the needs of the individual Fellows; and (e) the translational partnership with 4 major pharmaceutical companies. Furthermore, the presence of the Manchester Academic Health Science Centre and Liverpool Health Partners allows further integration of the programme within the NHS, important for access to patient cohorts and undertaking early phase experimental medicine studies, in the adult and paediatric clinical research facilities in both cities. The Fellows will also have access to state-of-the-art technologies through all the partners, enhanced recently in both Liverpool and Manchester through awards from MRC Clinical Research Infrastructure bids and by MRC investment in stratified medicine consortia, three of which are led from UoM.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool Health Partners</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Liverpool Health Partners</gtr:description><gtr:id>9F3E75E3-5250-4559-B3E2-A6348848CFA4</gtr:id><gtr:impact>Education Strategy across Liverpool Health Partnership 


Liverpool Health Partners, or LHP, is an umbrella organisation with a unique ability to bring together clinical and scientific expertise to develop and promote world-leading research, education, healthcare and innovation. Their work impacts not only the North West of England but also the rest of the UK and the whole world.</gtr:impact><gtr:outcomeId>56d6a8396868c9.77177556-1</gtr:outcomeId><gtr:partnerContribution>Liverpool Health Partners brings together the Liverpool City Region's leading hospitals and academic institutions to 
improve health and deliver exemplary research, 
education and healthcare, specifically in Personalised Health.</gtr:partnerContribution><gtr:piContribution>Executive Director of Liverpool Health Partners leading on the theme of personalised medicine. 

Drugs are an important element of the research, teaching and service delivery undertaken within the institutions involved in LHP. 
 1) Personalised Health related initiatives: A central part of the therapeutics theme is to foster research in stratified medicine. A key new initiative where the therapeutics theme will be intimately involved is the Liverpool Biomedical Research Centre. This will be enhanced by a development to establish a Biomedical Research Unit at Alder Hey Hospital. In addition, working with the AHSN, we aim to introduce some form of genetic testing into clinical care by working with a diagnostics company

One example is the FUTURE initiative. A project to develop a panel of healthy volunteers who have been genotyped for polymorphisms in drug metabolising enzyme and transporter genes, who can then be readily recruited for Phase I healthy volunteer studies. 

2) NW Genomics Healthcare Alliance: To develop a strategy to bring together the enormous expertise that is available within the NW Coast region. This should involve a consolidation of the existing strengths by leveraging this to develop a new model which places the region on the national map as a centre of excellence for clinical care, research and education. In late 2013, LHP established the North West Coast Genomics Healthcare Alliance (NWC GHA), supported by NWC Academic Health Science Network (NWCAHSN). Chaired by Professor Munir Pirmohamed, the Alliance brings together a range of clinical and academic genomics expertise from across the region, to look at the themes of research, education and services. Now looking at building genomics into Masters qualifications at the University of Liverpool, the Alliance will also be involved in several other upcoming bids in 2015.

? NWC GHA was responsible for coordinating the successful bid for the NWC Genomic Medicine Centre led by Liverpool Womens' Hospital and has established a range of genomics educational workshops for clinicians.

? Liverpool PRiME. LHP has been working with Liverpool Local Enterprise Partnership and NWC AHSN to develop the Liverpool Precision in Medicine Report, produced by Price Waterhouse Coopers. This report aims to bring investment into the region in the area of precision medicine, outlining several projects which are looking for longer term funding.

3) Pharmacovigilance in LHP: Reporting of adverse drug reactions to the MHRA is an important marker of quality of care of patients. There is wide variability in reporting at present. Having convened a working group, LHP aims to improve reporting of adverse drug reactions within LHP Trusts to make the region stand out in improving drug safety. This effort will be linked to improving education and training in this area, and will also involve the prevention of drug-drug interactions. The YCWG is exploring the possibility of holding an annual event in the Mersey region to engage practitioners further. Methods to engage patients and increase patient reporting are also under investigation

? The Yellow Card Working Group (YCWG). Established in May 2014 to improve adverse drug reaction reporting via the Yellow Card Scheme in LHP Trusts. A number of different initiatives and approaches have been adopted with overall reporting up 61% in 2014/15 compared with in 2013/14. 

. Liverpool Adverse Drug Reaction Causality Assessment Tool. A project to evaluate the implementation of the tool has been submitted to the CLAHRC North West Coast. 

4) Alcohol: Alcohol misuse remains a major cause of morbidity, mortality, hospital admission and social problems within the LHP patch. There are initiatives in the community to reduce the transition from social to problem drinking, and this preventive approach is clearly important. However, for the many patients who have gone beyond this point, and are classed as alcohol dependent, there is a need to better develop how we use drugs that prevent relapse to drinking. Four areas are being targeted: (a) define the pharmacoepidemiology of current drug use by using health informatics databases; (b) develop baclofen as a treatment for alcohol dependent patients with liver impairment; (c) stratify the use of naltrexone in patients by genotyping for the mu-opioid receptor; and (d) identify new biomarkers of hepatic fibrosis/cirrhosis, and identify new drug targets.The LHP Alcohol Research Alliance (LARA) has been established to foster closer working links between alcohol related researchers in the Liverpool region. The group consists of clinicians, specialist nurses, academics and policy makers, with the aim of developing cross theme programmes that will allow a range of translational research questions to be addressed.

? Alcohol Research Biobank. Initial funding has been secured from the Liverpool BRC in Personalised Health. Once established the team will be looking for larger, sustainable funding streams.

?GenomALC. A collaboration has been established with an international consortium (GenomALC) to investigate the relationship between alcohol consumption, genetics and progression to alcoholic liver cirrhosis.

? Alcohol Research UK has funded several Liverpool, and other national , projects to identify how drugs are used in the treatment of alcohol dependence.

5) Cardiovascular pharmacology: Cardiac disease is the major cause of death nationally, and working with 5LHCH, we intend to identify new areas which can be developed that will improve existing drug therapy and improve capability in the region. The warfarin example reflects a project which is far advanced, but other areas which are being discussed include personalised renal function monitoring in patients with heart failure being treated with diuretics and stratification of anti-platelet therapy.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Paul Sabatier University (University of Toulouse III)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>6CA732F8-E094-486C-9ED0-904704061925</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-9</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CyTof procurement</gtr:description><gtr:id>D9C08B6B-5E8B-44F8-9EEE-FAA714850B25</gtr:id><gtr:impact>Favourable cost reductions for all partners during procurement of seven individual CyTOF machines.</gtr:impact><gtr:outcomeId>56dffbe1030ec0.26607735-6</gtr:outcomeId><gtr:partnerContribution>Supporting Professor Beynon where necessary and appropriate</gtr:partnerContribution><gtr:piContribution>Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards
user-group network meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sengenics</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>Immunome Protein Array for Autoantibody detection in the circumstance of oncology immunotherapy toxicity (Munir Pirmohamed/ Anna Olsson-Brown)</gtr:description><gtr:id>58E21467-9B63-4CCA-9067-D8C6F5084956</gtr:id><gtr:impact>pending</gtr:impact><gtr:outcomeId>589c3d8bcb84e2.44634891-1</gtr:outcomeId><gtr:partnerContribution>provision of specific test for pilot study</gtr:partnerContribution><gtr:piContribution>Study design and sample provision for pilot study</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines for Malaria Venture (MMV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>MMV research project - primaquine</gtr:description><gtr:id>AFA5A4FE-DCBD-4C74-A682-5654AAA8C45D</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545cf58f54fd58.78188841-1</gtr:outcomeId><gtr:partnerContribution>Scientific input into project
Progress evaluation through monthly teleconferences</gtr:partnerContribution><gtr:piContribution>Scientific leadership and research activities from two postdoctoral fellows</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Federal Institute for Drugs and Medical Devices</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>55CA9C16-6A94-4559-8BCB-A3314FF70915</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-2</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ASCPT 2015 March 2015 New Orleans</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F12620F-0F16-426D-B4C9-B719C2D08C8D</gtr:id><gtr:impact>GREATER UNDERSTANDING OF PERSONALIZED MEDICINE USING GENOMEWIDE APPROACHES

INVITATION TO DISCUSS AT FUTURE EVENTS</gtr:impact><gtr:outcomeId>54f5789cacf4a3.99225685</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PSMN  WORKSHOP LONDON NOVEMBER 11TH 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B5D264B1-EFBD-4BB6-8293-23BB3E28F163</gtr:id><gtr:impact>Work shop identified and highlighted progress and innovation in the filed of stratified medicine.

Ability to learn from industry and other collaborative partners on future direction of stratified medicine</gtr:impact><gtr:outcomeId>564b13324e9d64.09914873</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Training Day for SpRs in Clinical Pharmacology</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F298095-03C5-4ACE-92EB-1FCBD651863D</gtr:id><gtr:impact>to assist with training as part of National Training Day for SpRs in Clinical Pharmacology

More infiormed trainees.</gtr:impact><gtr:outcomeId>54c8af8f740c82.57337207</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parliamentary reception 12th December 2016   Pharmacology's role in bridging the skills gap in UK bioscience industry&quot; and to be joint with the ABPI.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>484069F0-B899-4998-847B-930DDD64C0C0</gtr:id><gtr:impact>attended event as a representative of BPS On behalf of Stephen Metcalfe MP, to attend a special Parliamentary Reception, 'Is UK pharmacology a world leader? Bridging the skills gap in the biopharmaceutical industry'. 
The reception will be hosted by the British Pharmacological Society in collaboration with the Association of the British Pharmaceutical Industry (ABPI).</gtr:impact><gtr:outcomeId>583c28bdbb1cb9.15796677</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MHRA Innovation Symposium  30th November London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC159D32-FFB2-4C1E-A11F-E7613291BD11</gtr:id><gtr:impact>The MHRA Innovative Medicines Symposium offers industry professionals and academics the opportunity to hear from MHRA and experts from the Commission on Human Medicines (CHM) about regulatory considerations and support for innovative medicines and emerging technologies

Regulatory perspectives of emerging technologies presentation delivered - generated and stimulated thining in the cintrolled field of regualtions.</gtr:impact><gtr:outcomeId>56583fad860b55.26552647</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic Paediatric Association conference 2016  Alder Hey  Liverpool</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8CFBCAE4-0785-49ED-9B0A-F5963D832EEC</gtr:id><gtr:impact>?The annual Academic Paediatric Association conference Liverpool on April 14th and 15th. This is the preeminent conference for all paediatric trainees, allied healthcare professionals, scientists and consultants with an interest in academic paediatrics. areas of dicussion included Personalised medicine - discovery to implementation the application of nanotechnology in paediatric drug delivery -</gtr:impact><gtr:outcomeId>570e03137a7e11.41135473</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalised healthcare sensor event  15th March 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3FBE98FD-93EB-4F2A-B946-4440EB88476C</gtr:id><gtr:impact>Event raised and explored the issue of Mobile Health and Sensor Technologies as key drivers for Better self-management of illness, Point of care monitoring, and moving clinical care from secondary to primary care and outlining the key challlenges of 
Patient acceptability of biosensors
Integration and big data
Application and interoperability
Changing clinical pathways
Technological needs - near patient testing</gtr:impact><gtr:outcomeId>56ebb4e139e055.80453641</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with Justin Madders Shadow Health Minister / Lord Hunt re Clinical Pharmacology in NHS</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>32424390-7316-49CC-B915-832700F72B0C</gtr:id><gtr:impact>Promotion of Clinical Pharmacology in NHS</gtr:impact><gtr:outcomeId>56ea722445c1a8.25060274</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A Conversation with clinicians: shaping the implementation of genomics in mainstream medicine 7th June 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6CF2C5BE-B306-415F-9544-F03E0FDA4697</gtr:id><gtr:impact>Genomics England's engagement programme aims to catalyse discussions with the public and specific expert stakeholders about the potential of genomics, and issues likely to arise in its wider implementation within health services. This meeting is the only event focused on clinicians, and brings together 'clinical champions' from the PHG Foundation's Genomics in Mainstream Medicine initiative, alongside other senior clinicians from those fields. Offered a practical view on the potential of genomics for patients - and the barriers to be addressed to make it available in mainstream medical practice</gtr:impact><gtr:outcomeId>57612891828b11.11633309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPS Winter Meeting - 2017 (Vincent Yip)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F4BEF8A2-CE46-459E-AD2B-1283C4E37D98</gtr:id><gtr:impact>Oral Presentation of latest findings from PhD research</gtr:impact><gtr:outcomeId>58ac7163de5071.52770192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LHP / NICE CONFERENCE   liverpool 14.10.2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8DAEF642-2464-46DB-99EE-0ECFA937F08C</gtr:id><gtr:impact>dsicussion centred on How genetics can impact healthcare
- Increased availability of genetic testing and the future of primary care
- The importance of a free NHS in the era of genetic medicine
- Opportunities for personalised medicine


Increased knowledge and appetitle for Personalised medicine</gtr:impact><gtr:outcomeId>562e08723658d1.19442509</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with The Rt Hon Lord Hunt of Kings Heath PC OBE, Deputy Leader of the Opposition  4.5.2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F890B38-C8CD-4E84-B836-A097B50F9BC6</gtr:id><gtr:impact>discussion with The Rt Hon Lord Hunt of Kings Heath PC OBE, Deputy Leader of the Opposition in relation to Highlighting CPT / Clinical Pharmacology in NHS 

outcome PQs will be raised on topic</gtr:impact><gtr:outcomeId>572b45b5157385.14021024</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FOCUS 2015, the National Meeting of the Association for Clinical Biochemistry and Laboratory Medicine,9-11th June 2015 in Cardiff</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C82B7B64-E35D-4163-BAB5-0B2751632203</gtr:id><gtr:impact>To assist thinking and understanding to medical and clinical scientist consultants in clinical biochemistry and trainees at various stages to . purpose of this symposium is to update on scientific principles and to highlight any areas likely to be of particular relevance to the hospital diagnostic laboratory.

Improved learning and knowledge from audience</gtr:impact><gtr:outcomeId>5577e63e236d97.95149925</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genomic Medicine for Clinicians Conference January  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D2D7C469-0784-4B59-A4BE-65B31F03962E</gtr:id><gtr:impact>presented a talk on Pharmacogenomics &amp;amp; genomic drug development which generated discussion and interest in the subject matter

interest in the subject matter generated</gtr:impact><gtr:outcomeId>54c8ae4934e0a5.56844668</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Yellow Card celebration event Liverpool April  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B9B9F63F-AA34-4059-BAE7-810A7A170C1E</gtr:id><gtr:impact>to celebrate 50 years of the Yellow Card -an event was he;ld in merseyside to celebrate work undetaken as part if yellow card scheme presentation focussed on The Yellow Card Scheme the current research and future developments


greater understanding of work of yellow card and impact an d difference it has made . plans discussed for future of yellow card</gtr:impact><gtr:outcomeId>55268511797e14.99495733</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Launch of the NW Coast Genomic Medicine Centre  July 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6C197A6A-3916-43B9-8066-77E9DBA5C169</gtr:id><gtr:impact>To generate interest in and support for the Launch of the NW Coast Genomic Medicine Centre

to promote the issues of NHS Transformation through use of Genomics and precision medicine</gtr:impact><gtr:outcomeId>55b60e61b0af48.75453655</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Pharmacogenetics &amp; Stratified Medicine Network Open Meeting March 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>90514193-B246-4F48-9FF7-06C9BF8AE39E</gtr:id><gtr:impact>The Precision Medicine Catapult, the UK's innovation centre for precision medicine, and UK UK Pharmacogenetics and Stratified Medicine Network. are workig together in a strategic partnership to work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes.
'The UK Pharmacogenetics and Stratified Medicine Network has connected many of the leading stakeholders in the precision medicine landscape, two organisations to partner and deliver engagement . The two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes.</gtr:impact><gtr:outcomeId>56ebb687b48456.37739374</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.uk-pgx-stratmed.co.uk/images/stories/pdf/UKPGX2016_Programme.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint workshop MHRA - STRATIFIED  MEDICINE WORKSHOP June 9th 2016   Regulation of genomic testing</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>982C4A89-BE59-4094-9BB8-EF5AB4C9285E</gtr:id><gtr:impact>To discuss the Regulation of genomic testing and the challenges that arise from patient / professional perspective</gtr:impact><gtr:outcomeId>5761296dc977e3.20410562</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kuala Lumpar - Next generation pharmacogenomics March 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>45666914-1A62-43D6-932F-2B7B11B06ACD</gtr:id><gtr:impact>debate generated personalised medicine the challenging of developing the evidence base

students, academics and health professionals debated about such issues to inform discussion</gtr:impact><gtr:outcomeId>54f5a5de682b73.67547760</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EPSRC Centre for Mathematical Sciences in Healthcare -- Centre Launch Day May  2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>03BDFDC7-A29B-4978-B142-3DDE4665B13D</gtr:id><gtr:impact>Launch of EPSRC at UOL bringing together CIs, advisors, industrial and clinical partners, plus other UK Centre reps over for a networking day</gtr:impact><gtr:outcomeId>57359d3762b106.62185236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Better Safer medicines for Children and Babies (Alder Hey / UOL )</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6D1095D0-90B1-4935-83BA-85A47A193D92</gtr:id><gtr:impact>The intention is the establishment of a Biomedical research unit BETTER, SAFER MEDICINES FOR CHILDREN AND BABIES intended to integrate Liverpool's international expertise in Child Health, Clinical Pharmacology, Stratified Medicine, Drug Safety Science and Translational Biomedical Research, into the development of safe, effective and targeted therapies for children and babies to better address their current and future health needs. chairmanship of this group to drive forward</gtr:impact><gtr:outcomeId>56dee59b0f1443.11598537</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPS Winter Meeting Dec 2015 (Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBA0DB59-2506-4309-AB88-61B4854FED81</gtr:id><gtr:impact>Poster presentation of latest findings from PhD research</gtr:impact><gtr:outcomeId>56a0c411af0573.22377813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PGX and Strat Med Network meeting - Cambridge Jan 15</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>22879199-F07A-4C6C-8431-6F280477D0A9</gtr:id><gtr:impact>This meeting brought together leaders from academia, regulatory bodies, healthcare organisations, pharmaceutical and diagnostics industries to discuss recent progress in this area.

focus was on the UK environment for stratified medicine and will review current public and regulatory perceptions. It will also highlight developments in clinical trial design and advances in key areas of research; including pharmacogenomics, rare diseases, rheumatoid arthritis and cancer.


Sharing of information and recnet changes in areas of stratified medicine</gtr:impact><gtr:outcomeId>54b791d3678e08.50967365</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmacogenomics: A tool for precision medicine meeting organised by the Medical Genetics Section of the Royal Society of Medicine. NOVEMBER 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>88A81EDB-211E-4AFD-A2C0-0CD68AC8ABD6</gtr:id><gtr:impact>Pharmacogenomics: an overview for the uninitiated
f you are interested in finding out about how precision medicine is set to revolutionise medical practice, do not miss this event!

The section meeting focused on 
Introduce healthcare professionals to the concept of pharmacogenomics
Provide a realistic overview of the likely impact of pharmacogenomics in modern medicine
Share speciality-based experience of the role of pharmacogenomics in stratifying treatments to individual patients with an Explanation of how stratification in precision medicine can be achieved</gtr:impact><gtr:outcomeId>5820940d02fdb6.92415861</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Meet the Scientists', Liverpool World Museum, January 2016 (Richard Turner/Programme Coordinator)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5ED4DF11-88A1-4344-A12E-D32F8F0D2AAF</gtr:id><gtr:impact>A group of approx 20 PhD Students and Postdoc researchers from the Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine, including Richard Turner from the Fellowship Scheme took part in this large public engagement activity which was a callobration between the Faculty of Health and Life Science at the University of Liverpool and the Liverpool World Museum in the city centre. They hosted five activity stand exploring the development of evidence based medicine and new innovations in genetics, big data and bioinformatics that will contribute to the development of personalised medicine. This was done through a series of simple table top activities aimed at children which provided students and postdocs with the opportunity to talk to adults about personalised medicine, clinical trials, drug safety as well as talking about their own research. The vent was very popular with over 500 people visiting the five stands that were under the banner 'Marvellous Medicine'. Angela Foxcroft, the Fellowship Programme Coordinator and Kerrie McGiveron, the CDSS Research Administrator played a key role in organising this event. Richard Turner (MRC Fellow) developed the activity explaining 'Clinical Trials' and ran the stand for the whole day.</gtr:impact><gtr:outcomeId>56a88d1f12b884.39018236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PHARMACOLOGY 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EE350195-CC83-43C9-B462-9FE79D7756A1</gtr:id><gtr:impact>Key role in supporting the work of BPS to promote and advance pharmacology, including clinical pharmacology in the following ways:

Assist, promote and encourage research and provide a forum for the presentation of pharmacology
Publish the results of research
Promote and encourage the education and training of pharmacologists
Publish resources in various forms
Promote and arrange conferences and meetings 

Promotion of CPT in NHS is key objective</gtr:impact><gtr:outcomeId>56ebb8f22afaf8.81807631</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/pharmacology-2015</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSX Glasgow June  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D06120A3-F0C3-429E-B190-25AD585D846F</gtr:id><gtr:impact>presentation on Implementation of Pharmacogenomics in Clinical Practice-focus on evidence-based medicine and cost-effectiveness&amp;quot;.

Greater understanding on th need for cost effectiveness for the need of Pharmacogenomics in Clinical Practice</gtr:impact><gtr:outcomeId>55891afea3ad98.85134722</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK PGx Spring Workshop  April  2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>74FDB522-88CE-4154-BEB6-378906A34498</gtr:id><gtr:impact>aim of workshop in conjunction with MHS England was to discuss and take forward the Re-engineering of clinical pathways to facilitate implementation of personalised medicine featuring six talks to outline existing strategies and pathways. delegates discussed

Barriers to changing clinical pathways for personalised medicine

Patient and clinician involvement in pathway change and implementation

Use of electronic technologies to aid re-engineering of clinical pathways</gtr:impact><gtr:outcomeId>5720970daded33.57626309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.uk-pgx-stratmed.co.uk/index.php/latest-news/31-news/latest/385-ukpgx-spring-workshop-2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SJS AWARENESS LAUNCH February 2015 - London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>696AC2D9-6581-4EDE-B27D-3BA6642E46A4</gtr:id><gtr:impact>To raise awareness of Stevensd Johnson syndrome at an event in Hosue of Commons to gain support form Decision makers to raise awareness of SJS and to request support for a national awareness day for SJS ,

Committment to raise awareness of SJS amongst health professionals</gtr:impact><gtr:outcomeId>54c8b1853af2b3.13044640</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with Rt Hon Sir David Willets MP   2ND June  2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5EBB814A-2DC0-470E-AE9C-B258B4E4D8B1</gtr:id><gtr:impact>Discussion with Rh Hon David Willets on work undertaken at the Wolfson centre for Personalised medicine and future initiatives and research areas.
engagement with staff , research nurses , Post docs was undertaken to demonstrate the broad scope of work undertaken.</gtr:impact><gtr:outcomeId>576127ba259249.50446565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Singapore - joint scientific advisory board STAR BOARD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>171090EA-5109-48AE-A9B8-61FE119BC723</gtr:id><gtr:impact>the BMRC decided that they will use the title 'Scientific Review Committee' for any expert committee advising upon a research programme.

improved understanding and increased collaboration

sam</gtr:impact><gtr:outcomeId>5555c2a43b7cb1.95833254</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Deep Leaning Precision medicine Workshop Riva Del Garda September  2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1484EF91-9F89-4169-AC3C-F54A8BDE82BB</gtr:id><gtr:impact>greater awareness of impact of deep learning on precision medicine</gtr:impact><gtr:outcomeId>57e50bc8322966.43138385</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medicine in 1925 and in 2015: a symposium to mark the 90th Anniversary of the Postgraduate Medical Journal  1st october 2015 London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3AC04D0E-F1BA-4859-A63F-4B72EA28129F</gtr:id><gtr:impact>presentation Progress in Personalised Medicines stimulated debate in the advancements of medicine from 1925 to present day.

request for further information in respect of topics covered in speech</gtr:impact><gtr:outcomeId>560d1e0a1faa83.39590821</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SJS/TEN CONFERENCE BETHSEDA MARCH 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1CCEC414-B98B-4D8D-B470-08F46FA40002</gtr:id><gtr:impact>iSAEC and what has been done in this area stimulated discussion in this area and what advancements can be made

sharing of information and a greater understanding of work being undertaken in other countries such as Malaysia and Thailand</gtr:impact><gtr:outcomeId>54f57603dac918.54498133</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary talk at British Oncology Pharmacists Symposium Manchester -October 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F08D1473-1BD9-46DC-922F-2C9A5CE8B764</gtr:id><gtr:impact>19th Annual BOPA Symposium being held at Manchester Central.
 
The BOPA Annual Symposium is a highly significant event in the UK oncology and pharmacy calendars, attracting over 500 delegates, 40 pharmaceutical companies, and representatives of cancer charities, the NHS and government bodies involved in the delivery and co-ordination of cancer services. Delegates are pharmacists and pharmacy technicians involved in the care of cancer patients and the management of pharmacy and chemotherapy services in cancer centres, primary care and NHS England organisations.</gtr:impact><gtr:outcomeId>57ff90f04c0c30.27008474</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bopawebsite.org/user/login?maintenance=mode</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCPE Midlands Symposium, April  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>88C7A796-11CA-48B2-82EB-B7B8E7DC1C62</gtr:id><gtr:impact>The RCPE organises a number of regional symposia in different parts of the UK. All grades of medical and other healthcare staff attend 
 Topics covered on the day included cardiovascular medicine, gastroenterology, complex care of older people and stroke medicine, with the Dr Andrew Duncan Lecture delivered by Professor Sir Munir Pirmohamed on the topic of Personalised Medicine - How will it shape medicine in the future</gtr:impact><gtr:outcomeId>570e01084bcca5.94649795</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://events.rcpe.ac.uk/events/409/regional-symposium-midlands</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DHM 2016 Malaga</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>96631F22-AFBE-4AAF-B1E0-EE60D4841D73</gtr:id><gtr:impact>Brought together researchers and physicians from different disciplines to exchange their most up-to-date data in this continually evolving field and to transfer it to clinical practice</gtr:impact><gtr:outcomeId>571f34112a4ea1.05643116</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.eaaci-dhm.org/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gordon Research conference MAINE  June 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8CB7ACFD-9E2A-4396-9F37-465B848FC325</gtr:id><gtr:impact>a speaker on the topic &amp;quot;Translational Safety &amp;amp; Patient Tailoring&amp;quot; at the 2016 Drug Safety Gordon Research Conference. As an expert and thought leader in that area your contribution would be invaluable to the success of the conference and to openly discuss the current state and future direction of using pharmacogenomics in drug safety assessment. 

The 2016 Drug Safety GRC builds upon a successful inaugural meeting in 2014 and aims to discuss current and future approaches in drug safety assessment. The goal of our conference is to bridge the divide that exists between individuals working in predictive, pre-clinical and clinical drug safety research, and to foster the translation of innovations from the lab to the clinic. In 2014 session chairs, speakers and participants from academia, industry and regulatory agencies used the opportunity to network and identify current practices and needs in drug safety assessment and to discuss advances, opportunities and limitations of novel translational drug safety methods.</gtr:impact><gtr:outcomeId>577a542310e7d9.67256949</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.grc.org/programs.aspx?id=16738</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>11th International ISSX Meeting: South Korea June 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>708204D7-A8F3-420C-9573-09EE447A406E</gtr:id><gtr:impact>Plenary lecture Pharmacogenomics: relevance to personalised medicine&amp;quot;
Symposium Non-HLA Genetic Risk Factors in Idiosyncratic Adverse Drug Reactions title of presentation is: Statin-induced Myotoxicity</gtr:impact><gtr:outcomeId>57612ab05c19b2.58411600</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://issxbusan2016.org/schedule-at-a-glance-1/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2016 KSCPT Spring Conference, Busan, Korea</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D0EA49D3-E401-4D86-BF11-06A1D45665B4</gtr:id><gtr:impact>speech title Precision Medicine: A Clinical Pharmacological Perspective. -</gtr:impact><gtr:outcomeId>57612b13147916.30802348</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>pharmacogenetics-conference .South Africa April  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>940A6D68-9B2D-4F7F-BCB1-6C576CF0A5AA</gtr:id><gtr:impact>Genomics research is on an upward trajectory in Africa since the inception of H3Africa and the event has showcased there are very good papers from across Africa and around the world.

lectures Genomics and Therapeutics plenary lecture and speech Genomics of the bug and host as determinants of drug response</gtr:impact><gtr:outcomeId>57062625c10fe4.55831505</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.pharmacogenetics-conference.uct.ac.za/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ATTENDANCE AT PHARMACOLOGY 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1FA10386-DC3C-4650-AED2-897C7C556364</gtr:id><gtr:impact>4 DAY EVENT IN WHICH DISCUSSION AND DEBATE WHERE GENERATED

Ideas shared and information built upon</gtr:impact><gtr:outcomeId>54abd61dcf1162.08075123</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC BIANNUAL Directors Meeting MAY 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4D624FEF-2FE2-427C-813B-8878589F062F</gtr:id><gtr:impact>MRC BI ANNUAL Meeting to discuss areas of interest and progress in MRC activities</gtr:impact><gtr:outcomeId>576124f1874401.81391718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Athens UPGX  meeting 26th September -28th September  2016 the 1st Annual Consortium Meeting,</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>115A7F0B-27DB-4973-A51E-945ED2AF7BA0</gtr:id><gtr:impact>the 1st Annual Consortium Meeting, Athens
to discuss 
Kick-off meeting report
planning for Reporting Period 1, including Meetings, U-PGx Days, Deliverables and Milestones.</gtr:impact><gtr:outcomeId>57f37e324f7fb5.61527792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference Feb 2015 Cardiff  - Digital Health Assembly,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1E7E0B9E-FA24-42A7-9565-2E3670464234</gtr:id><gtr:impact>big data topic on the subject of: 'My Risks, My Treatment: Stratified Medicine'

eHealth Industries Innovation (ehi2) Centre in partnership with the Farr Institute and the Welsh Government hosted the meeting Over three days speakers covered three main topic areas of big data, innovative business models and empowering patients and staff which ensured the event was illuminating and insightful one</gtr:impact><gtr:outcomeId>54d2254e8818b1.00864983</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmacology  2016 London  13th -15th Decemeber</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6A9A36D4-541F-49DD-89BE-72728277CD27</gtr:id><gtr:impact>Pharmacology is the flagship annual meeting of the British Pharmacological Society and attracts over 1,000 scientists each year, mostly from the UK but also many from across Europe and from overseas. The meeting includes a selection of topical symposia, plenary lectures, free oral communications and poster sessions which cover the whole spectrum of pharmacology.

key topics covered Cardiovascular and Respiratory Pharmacology
From bench to bedside: targeting the pathophysiological responses of ischemia-reperfusion injuries
Targeting cardiovascular GPCRs using biased agonism
Nanomedicine in pharmacology
 
Neuropharmacology
Uses and challenges for human pharmacology studies to understand CNS diseases
Fatty acid amides (aka lipoamines) beyond cannabinoids
Recent developments in research of melatonin and its potential therapeutics application
 
Integrative Systems Pharmacology
The long reach of the bowel: Translating microbiome science into therapeutics for systemic human diseases
Study, development and rationale use of immunopharmacological agents
Immuno-oncology: From bench to bedside
Translation to Therapeutics: Resolution of Inflammation
 
Molecular and Cellular Pharmacology
Non-traditional/orphan GPCRS as novel therapeutic targets
Biochemical strategies in drug discovery and targeting
Anti-tumor pharmacology and traditional Chinese medicine
 
Drug Discovery, Development and Evaluation and Toxicology
Organ-on-a-chip technology - the future of physiological profiling?
Clinical application of systems pharmacology models
Clinical pharmacology, pharmacokinetics and pharmacogenetics in pregnancy (C4P)</gtr:impact><gtr:outcomeId>583c27e01c0907.34094537</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>https://www.bps.ac.uk/pharmacology2016#Programme</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International symposium on Advances in Predictive &amp; Personalized Medicine Istanbul April 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6A8A179D-D48A-43FD-BE6A-1242A59289AE</gtr:id><gtr:impact>Keynote Speaker Invitation for International symposium on Advances in Predictive &amp;amp; Personalized Medicine

Kay note speech focuseed on How to Select Pharmacokinetic Tests for Population Health? Lessons Learned at the UK National Health Service (NHS)&amp;quot;. which helped stimulate debate and discussion on the issues around predictive and personlized health</gtr:impact><gtr:outcomeId>5526829d415478.35157843</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chief Scientific Officer Conference 1st March 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A023D476-29FC-4F13-82D0-C3B3F3F2289A</gtr:id><gtr:impact>The Vision For 2020 is aimed at senior leaders and healthcare scientists at all levels to start encouraging them to look to the future. healthcare scientists across all disciplines attended the event with the aim to show the depth and breadth of expertise that there is the event covered key changes and challenges in the healthcare and healthcare science landscape,
1. Science at the heart of the constitution
2. Healthcare Scientists delivering the change 
3. Emerging science 
4. Building the capacity and capability for change 
my contribution was bringing my expertise and knowledge to the theme of Personalised medicine</gtr:impact><gtr:outcomeId>56cef6384a5784.28236668</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Spectacular 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>68FE7123-2C63-4776-8237-6560C5877E95</gtr:id><gtr:impact>The Manchester Science Spectacular runs annually and is an opportunity for scientists to showcase their research work to an audience of children and families. The event is attended by approximately 1,500 people.

Interactive table top activity aimed at families and children to teach about medicine and where it comes from as well as personalised health. Several MRC Fellows took part in the event. Approximately 100 children took part in this activity.


This is the fourth year MRC Fellows have taken part in this event and the stand Marvellous Medicine has become a regular acticity stand at this event.</gtr:impact><gtr:outcomeId>5672b8917074e6.89842394</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wolfson Centre Patient Involvement Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E5F37C62-7A8B-4DC7-9AFC-BCD1776E39D9</gtr:id><gtr:impact>We have established a patient and Public Involvement group. The purpose of the group is to offer the opportunity for group members to work alongside researchers during the set up and conduct of research studies.

Ongoing. We are working with the patient group to establish an awareness campaign about Stephen Johnson Syndrome aimed at clinicians. We are also supporting the 'SJS Awareness UK' group by updating patient information on their website.</gtr:impact><gtr:outcomeId>LTT5CgLV84a</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ELRIG Drug Discovery conference October 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5ADD0258-682B-4FEF-878F-7EB4E5036A2F</gtr:id><gtr:impact>Plenary lecture 45 minute presentation of broad appeal to mostly preclinical 'drug discovery' in drug discovery research across pharma, biotech, academia and the vendor community.
The meeting will feature over 50 invited speakers in 6 main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success. Scientific tracks will cover therapeutic areas (e.g. oncology &amp;amp; immunotherapy), innovative technologies (e.g. assay development, screening, chemistry), and target progression challenges (e.g. target identification/validation, translational models). d.</gtr:impact><gtr:outcomeId>57ff8ff4192a69.18834938</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://elrig.org/drug-discovery-2016-programme/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalized Medicine 2015 Conference - Saudi Arabia 5th May -7th May</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CC9A4DA9-ACAC-424A-B102-BA080954BA88</gtr:id><gtr:impact>Arab world has been under represented in International genome studies. The structure of the Arab population has much to offer in the field of genomics and are attempting to address this through the Saudi Human Genome Program. the talk assisted in enabling the hospital to continue this work However, the greatest challenge faced is in leveraging their genome program to address cancer, cardiovascular disease, obesity, diabetes and other common disorders and to deliver the promises of personalized medicine.

Pharmacogenetics is central in all of these areas It has also opened up opportunities to collaborate in a way where the unique population in which we work may be used to supplement international efforts in progressing pharmacogenetic investigations.</gtr:impact><gtr:outcomeId>554b1488f11000.92605302</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sanger Institute BioData World Congress October 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7BCB51D1-9774-439E-8A8B-3FCE1F38D9B8</gtr:id><gtr:impact>its second year is held in partnership with: The Wellcome Trust Sanger Institute, EMBL-EBI, Global Alliance for Genomics and Health, Babraham Institute, ABPI, Pharmacogenetics and Stratified Medicine Network, BIA, Pistoia Alliance, Cancer Research UK, Francis Crick Institute and the Farr Institute. 
I very much would like you to give a presentation at the meeting as I am well aware of the work that you are you are conducting in field. 
This year's event will:
? Examine the science and technology that is shaping and revolutionising our understanding of complex biological processes
? Review the game changing innovation, roadblocks, critical success factors in the utilisation of bio data
? How big data is driving developments in personalised medicine
? Bring senior scientists within academia, pharma and biotech companies in order to facilitate discussion and partnerships
 
 
The meeting covered 

? Personalised Medicine
? Clinical trials
? Computational biology
? Big Data
? Cloud computing
? High throughput technologies
? Next generation sequencing
? Pharmacogenomics
? Molecular diagnostics
? Biomarkers
? Infrastructure and security
? Data handling and management 
 
Presentation on &amp;quot;Advances in the Pharmacogenomics of Adverse Drug Reactions&amp;quot;</gtr:impact><gtr:outcomeId>5810b775c19963.45824239</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.healthnetworkcommunications.com/conference/biodatA/index.stm</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>6th International Conference Medical Genetics and Genomics in Healthcare Kuwait December 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BEDFE651-3E31-49A8-9255-2510ED131D37</gtr:id><gtr:impact>The conference will cover a number of genetic disorders, focusing on how the use of Next-Generation Sequencing (NGS) has transformed healthcare organizations. Keynote speakers around the globe discussed the clinical benefits of omics fields in diagnostic and research for genetics disease. The conference will also have an overview discussion of the achievements and challenges upon the implementation of National Genome project in Gulf Cooperation Council countries. Topics covered: - Clinical genetics and counselling - Neuromuscular, cancer, cardiac, and metabolic genetics - Next generation sequencing as diagnostic tool - Pharmacogenomics and metagenomics in health - Preventive genetics - Newborn screening - New treatments for genetic disorders</gtr:impact><gtr:outcomeId>583c26ca809374.36848557</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://algenome.com/conference/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kuala Lumpar - Visiting Lecturer  July 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5CE1E4CA-407D-43C1-8FEF-652B4EA751CB</gtr:id><gtr:impact>Series of talks to University of Malayisia Students and other Universities at undergrad, post graduate and academic staff on a rnage of topics aimed at promoting the realms and possibilities of Pharmacogenetics

Promoting the numbe rof opportunities and ideas within Pharamcogenomics</gtr:impact><gtr:outcomeId>559a976dcf01f8.26571694</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific Advisory Board Meeting NOVEMBER  2016 LONDON</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1B24436F-2A20-4924-9BEB-0A98FF077CB5</gtr:id><gtr:impact>AIM HY Original MRC Grant Application scientific meeting to determine requirements and support for grant</gtr:impact><gtr:outcomeId>582439be37f3d0.73946301</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SAPhIRE SRC meeting and Symposium  Singapore May 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B608501A-A1D5-4D67-9F54-5FE9FA2DBC65</gtr:id><gtr:impact>to focus on activities in Singapore / far east on issues surrounding pharmacogenomics in South east Asia and its development</gtr:impact><gtr:outcomeId>576126912897a7.28965686</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>N8/MRC Visit to University of Liverpool 25 04 2016 to discuss target in new Medicines</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F15425B4-80D4-4F00-88BA-65F58B3305CF</gtr:id><gtr:impact>Some thoughts from MRC colleagues on their strategic priorities followed by round table discussion and agreement on any next steps.</gtr:impact><gtr:outcomeId>571f353f38cb53.66446540</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC SHOWCASE March 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4E2F2CAF-F134-4F12-85E0-13D1BD8FD777</gtr:id><gtr:impact>showcase the work of the fellows with MRC TO OFFER SUPPORT AND GUIDANCE TO THE FELLOWS

Fellows supported and work undertaken recognised and acknowledged</gtr:impact><gtr:outcomeId>54f5a6af3a3553.09139177</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AASLD Hepatoxicity Special Interest Group Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF645E7C-E5A3-4FC8-B169-79D5A9B32570</gtr:id><gtr:impact>This was an AASLD hepatoxicity special interest group presentation.</gtr:impact><gtr:outcomeId>56b9ae097bc734.70421619</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh International Conference of Medicine: Past, Present &amp; Future - 12 &amp; 13 September 2016 RCPE</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F3321A10-C192-4115-B5BD-2C7C864D666C</gtr:id><gtr:impact>This event combine historical aspects of medicine with a glimpse into the future for healthcare across a broad range of clinical topics The audience consisted of a spectrum of healthcare specialists ranging from doctors in training through to senior consultants, nursing, physiotherapist and pharmacists. Lay representatives, historians and patients attended also 

two speeches given Pharmacogenetic variation - is it important for clinical care?&amp;quot; and what's on the horizon session: Precision Medicine&amp;quot; to link the issues of the background/ historical background to pharmaogenomics and discussing future potential going forward.</gtr:impact><gtr:outcomeId>57d7b5b7ef2ea7.89246312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.pastpresentfuture2016.org/home</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalised Medicine Conference in Oxford April 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>471042F4-7FED-4510-B2DC-1B8B60F0C1EB</gtr:id><gtr:impact>The conference is jointly organised by the Centre for Personalised Medicine in Oxford (a collaboration between the Wellcome Trust Centre for Human Genetics in Oxford and St Anne's College) and the PMWC 
 
A series of these conferences, organised by PMWC, have been held very successfully every year in Stanford. The Oxford conference will be the first of this series in Europe. 300 people, drawn from industry, academia, and the healthcare sector, to gather in Oxford across the three days for a conference focused on where personalised medicine fits in the clinic and on the practical applications of personalised medicine both now and in the near future.
 

 


insights and expertise in my role as NHS Chair of Pharmacogenetics provided a valuable addition to the conference</gtr:impact><gtr:outcomeId>552e79b5d92622.95232116</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISOP AGRA 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0E19407F-FE5F-46D0-816F-22B3FC95D42C</gtr:id><gtr:impact>Introduced As the host city for ISOP 2017 a prestigious honour to hold the THE Annual meeting on Pharmacovigilance internationally

Took part in BREXIT Debate at the ISOP 2016</gtr:impact><gtr:outcomeId>5804b81ea740e5.01574821</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.isop2016agra.org/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>POLANI LECTURE February  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B270CE32-980F-4B07-85B1-71D43EE07A9F</gtr:id><gtr:impact>POLANI LECTURE at Guys hospital makeup of the audience was geneticists, bioinformaticians, immunologists, dermatologists, clinicians, research workers (ranging from heads of groups to research students), and other interested parties. 

confirmed title Precision Medicine and Drug Safety: Opportunities and Challenges&amp;quot; followed by informal chat with Students</gtr:impact><gtr:outcomeId>56b872bc307525.07738218</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PPI Engagement event 8th April  2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>65DBB943-DB1F-4FC4-9788-2D2E94872634</gtr:id><gtr:impact>PPI patient group updated on progress within the international community of progress made in thinking on SJS/ TEN

the PPI team where invigorated by the progress made internationally to raising awareness of SJS/ TEN and impacts it has going forwatd to raise greater understanding and awarness of healthcare professionals.</gtr:impact><gtr:outcomeId>552683be812bf1.36413118</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Engagement Workshop 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B0D367C5-52A9-4AC3-A597-77F351F52BC5</gtr:id><gtr:impact>This public engagement event ran on 16th June 2015. There were approximately 50 attendees. The aim of the workshop was to help researchers and students understand pubic engagement. We had a variety of speakers, from Press Officer professionals to a Wikipedia expert. The event was well received with a lot of positive feedback.</gtr:impact><gtr:outcomeId>56cad866478323.66637678</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IBIMA - Malaga march 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F3DC20E3-9AAE-4466-8F44-775BEEFEA20F</gtr:id><gtr:impact>Regular seminars are a major part of the Instituto de Investigaci&amp;oacute;n Biom&amp;eacute;dica de M&amp;aacute;laga, IBIMA (Malaga Biomedical Research Institute) educational program. The aim of these seminars is to discuss research topics of interest for IBIMA with recognized experts in the field focusing on the most recent scientific discoveries. I Participated in a seminars as a speaker on the topic &amp;quot;Precision Medicine: its application in clinical investigation and practice innovation&amp;quot;.</gtr:impact><gtr:outcomeId>56d856a89c41c2.46420590</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Summer School GENOMIC MEDICINE - Bridging research and the clinic Portoro?, Slovenia May 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CFE104C5-0CFE-4412-9B87-1B9860CF271E</gtr:id><gtr:impact>shared expertise with the participants of the summer school and participate in the scientific programme. The program covered a wide range of topics related to genomic medicine ), pharmacogenomics and epigenomics and translation of basic research into clinical practice and public health. Important topics of interest were identification of predictive and prognostic biomarkers and novel molecular targets for tailored therapeutic interventions for diseases linked to oxidative stress and age-related diseases and disabilities. Rare diseases and rare cancers, especially epidemiology, pathogenesis/pathology, and treatment modalities for pancreas cancer will be among the topics of the school.</gtr:impact><gtr:outcomeId>572b4b7422c808.19656002</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://ibk.mf.uni-lj.si/genmed2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CDSS Scientific Advisory Board meeting April  2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5420D9DA-A4AD-4A0F-ABD0-C0D6D7EF9E51</gtr:id><gtr:impact>Event open to CDSS community to discuss key areas of research within the Centre 
Liver toxicity
? Biomarkers
? In vitro systems
? Regenerative medicine 
. Hypersensitivity
? Functional work
? Genetics 
GI toxicity
? Upper GI toxicity
? Lower GI toxicity</gtr:impact><gtr:outcomeId>56fe36361a4fd3.53993002</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Farr Institute International Conference 2015, St Andrews, 26 - 28 August 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>819A0394-5F36-4705-88B4-A2DB21ED42C3</gtr:id><gtr:impact>share thinking on the linkage with record darta and health informatics

researchers/ policy makers keen n the subject matter of topic of Linking Phenotype and Genotype</gtr:impact><gtr:outcomeId>55dc256e70ecd1.02411430</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmacological Society annual flagship meeting (2015) (Richard Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C58A0BEA-6542-47D0-B05F-848DA7B92623</gtr:id><gtr:impact>This was a presentation, entitled 'Investigating the prevalence, predictors and prognosis of suboptimal statin therapy early after a non-ST elevation acute coronary syndrome' concerning the the research Richard Turner has been conducting as part of his Fellowship on the North West England MRC Scheme in Clinical Pharmacology &amp;amp; Therapeutics. The presentation was well received and led to a thought-provoking discussion.

Richard was awarded the GlaxoSmithKline Prize for clinical oral communications as a result of this presentation at the British Pharmacological Society flagship annual meeting.</gtr:impact><gtr:outcomeId>56a8e36e5de837.72515623</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/pharmacology-2015#</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>YC 50th anniversary Edinburgh March  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4C037B7C-0518-4FEB-8591-71830153211A</gtr:id><gtr:impact>DISCUSSED THE ROLE OF Pharmacogenomics and the potential for the Yellow Card Scheme to stimualte thinking

discussion of the importance of yellow card scheme to best develop linking it to pharmacogenomics</gtr:impact><gtr:outcomeId>54f97d75771e70.94047113</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint ASCEPT-BPS Scientific Meeting May  2015  hong kong</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C190B8E-3A29-4C16-833E-7867AE755489</gtr:id><gtr:impact>symposium Phenotyping vs genotyping in HK slot of presentation 
presentation delivered &amp;quot; Has genotyping fulfilled its hopes to individualise drug therapy&amp;quot; and chared a session on Drug Discovery, Development And Evaluation

debate stimluated on the presentation delivered &amp;quot; Has genotyping fulfilled its hopes to individualise drug therapy&amp;quot; outlined next steps in this areas</gtr:impact><gtr:outcomeId>5555c1cdb13570.49299192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://ascept-bps2015.com/programme-and-keynote-speakers-2/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>6th Burns festival of Bone and Joint Disease  January  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D41E8373-603A-4041-9B77-88BD8BCC17C5</gtr:id><gtr:impact>talk at festival on Personalised medicine in rheumatology - fact or fantasy to stimulate thinking in this area.

Generated discussion and linkage between the various talks delivered to inform debate and discusion</gtr:impact><gtr:outcomeId>54c8b04c2fdd97.71650792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MADRID IFCC TF-PG : Task Force meeting   18th March 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>28E9FA4F-1467-40F8-9B4C-4FAACD59407C</gtr:id><gtr:impact>review of work achieved and planned collaboration going forward.</gtr:impact><gtr:outcomeId>56ebb762c00e52.57697266</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ifcc.org/ifcc-congresses-and-conferences/ifcc-gc-2016-madrid-es/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Utrecht Institute for Pharmaceutical Sciences (UIPS) of Utrecht University  October 2016  - Keynote speech</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0BD7CDEE-AE10-4F85-94EA-AC48B68CBA9F</gtr:id><gtr:impact>symposium &amp;quot;Bioinspired therapies UIPS is conducting research from molecule to patient populations, where our division of Pharmacoepidemiology &amp;amp; Clinical Pharmacology is focused on the last stage of drug development.</gtr:impact><gtr:outcomeId>5810b83609c728.86851250</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Health is Wealth conference Liverpool Jan  2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B68D54C4-5571-41C0-A5F1-EB4995451B80</gtr:id><gtr:impact>The purpose to highlight the development, progress and outputs of academic-industrial partnerships in early clinical translation.



The purpose of the workshop is to highlight the development, progress and outputs of academic-industrial partnerships in early clinical translation.</gtr:impact><gtr:outcomeId>54b792b3035204.13927456</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parliamentary Reception 14th december  2015 - BPS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D37D5132-10D6-416A-A425-F851683FD772</gtr:id><gtr:impact>To discuss and promote CPT guidance in NHS

further request for attendance at NHS England meetings and with chief medial officers in Scotland, Ireland and Wales</gtr:impact><gtr:outcomeId>56852654f18a90.48579305</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>  13th International Congress of Human Genetics (ICHG 2016) kyoto April  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>22A8FC99-24E5-4F6E-A45D-FDDCD3EE57C0</gtr:id><gtr:impact>session conveners to 13th International Congress of Human Genetics (ICHG2016) Recent spectacular advancement in the technologies of genome analyses including next generation sequencing and in the informatics of huge data including genome sequences and medical information, are bringing exceptional opportunities for better understanding our human genome and diseases, and, furthermore, for developing more efficacious treatment for diseases. the conference showcased many exciting scientific sessions in all the fields of human genetics. the conference enabled an opportunity to share latest development in human genetics and discuss the future of human genetics.</gtr:impact><gtr:outcomeId>56fe382b5830e3.10284423</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ichg2016.org/contents/program.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UPGX MEETING GRANADA 1ST DECEMBER  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E52628C3-3E7C-4754-A72C-327ACD1C88BC</gtr:id><gtr:impact>talk focused on Genomics of drug hypersensitivity reactions This event is open for healthcare professionals, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.

 The U-PGx project aims to address major challenges and obstacles for implementation of pharmacogenomics (PGx) testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach, data on multiple important pharmacogenes are collected prospectively and embedded into the patients' electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalized medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia)</gtr:impact><gtr:outcomeId>583c24b9d32495.08728202</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.goldenhelix.org/index.php/education/golden-helix-conferences/pharmacogenomics-days/upcoming-pharmacogenomics-days/#scientific-program</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Wellcome Trust Workshop on Pharmacokinetics/Drug Interactions MARCH  2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>44D75826-C011-4380-9DCB-DF5C5DD75005</gtr:id><gtr:impact>workshop around the general topic area of pharmacokinetics/drug interactions to explore emerging opportunities and to link researchers with complementary expertise and interests.</gtr:impact><gtr:outcomeId>54f9795580bdd4.56000490</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1st PHARMACOGENOMICS ISTANBUL SUMMIT 2015&quot; -iSTANBUL 26th November -27th November 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>48E877E2-CF42-4F7C-A59E-EF5FD9193592</gtr:id><gtr:impact>Pharmacogenetic Markers of Drug Efficacy and Toxicity talk and chairing a session on NOVEL TOOLS AND TECHNOLOGIES IN PEROSNAL OMICS RESEARCH

Although there have been significant advances in pharmacogenetics over the last decade, only a few have been translated into clinical practice. The best example is the implementation of HLA-B*57:01 genotyping prior to the prescription of abacavir, which has virtually eliminated the problem of abacavir hypersensitivity. With new rapid genotyping technologies, regulatory modernisation, novel clinical trial designs, systems approaches and integration of pharmacogenetic data into decision support s</gtr:impact><gtr:outcomeId>56583e9a159866.89387988</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.pharmacogenomicsistanbul.com/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DSRU's 8th Biennial Signal Detection Conference  June 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F5B2BB2-0258-4561-986B-E4B939DD03EF</gtr:id><gtr:impact>TO ENGAGE WITH Pharmaceutical companies from Europe uk USA to discuss progress in The pharmacogenetic basis of adverse drug reactions

improved knowledge</gtr:impact><gtr:outcomeId>557ed965ae0569.07487826</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Biophysical Society 2016 Biennial Meeting July 2016 Liverpool</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CAB9C07E-F04E-4AA8-9748-C0794485CFAF</gtr:id><gtr:impact>title of speech Role of transporters in drug failure the conference is dedicated to sessions covering cutting edge biophysical approaches to areas of major interest to the wider community.</gtr:impact><gtr:outcomeId>577a5ac9065ca7.86330664</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.britishbiophysics.org.uk/our-meetings/119-bbs2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The 21st International Reid Bioanalytical Forum (2015) Dried blood spot assay development poster presentation (Richard Myles Turner)   (Richard Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4CE5681A-35D6-46AD-8BF1-AC3E21D176C6</gtr:id><gtr:impact>Richard Turner was involved in the assay development and data acquisition that was presented at this international conference by Dr Mark Bayliss within a poster entitled, 'Dried-blood spotting combined with fused core HPLC-MS/MS for the measurement of atorvastatin, simvastatin and rosuvastatin in support of PK studies in the mouse'. Authors listed are: Bayliss M, Turner R, Kitteringham N, French N, Park K, Pirmohamed M. The presentation sparked further talk regarding micro-sampling techniques, and we were informed about a potential new card material that should overcome the haematocrit limitation of current dried blood spot technologies. This activity provided publicity for our ongoing work</gtr:impact><gtr:outcomeId>56a88e42d3c665.46767292</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bmss.org.uk/Docs/BioForum%202015%20second%20circular%20FInal2-1.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CDSS workshop to discuss drug-induced pancreatic injury  Liverpool September 30th 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE49315B-7E60-4115-B9FC-B455C32755C7</gtr:id><gtr:impact>Introduction to clinical problem, mechanisms of injury, risk factors for injury and emerging biomarkers and Industry perspective and better predictive models of pancreatic injury</gtr:impact><gtr:outcomeId>57f380d7d797e6.26280865</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2006,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>3rd Precision Medicine Congress  12-September  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D7D84E1A-2688-42C2-90A5-2844A2677B63</gtr:id><gtr:impact>keynote Address title Pharmacogenomics and its role in precision medicine 
 The conference had four streams over two days targeting the following strategic and scientific key areas:- 

? Strategies &amp;amp; Technologies to Enable Successful Implementation of Precision Medicine
? Biomarkers &amp;amp; Companion Diagnostics Development to Deliver Precision Medicine
? Integrating Personal Genomics, Big Data and Bioinformatics
? Precision Medicine Therapeutic Case Studies</gtr:impact><gtr:outcomeId>57d7b42d4e4983.71314522</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.globalengage.co.uk/precision-medicine.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PHARMACOLOGY 2015 LONDON</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4EE9D13D-3E1D-4BD6-882A-96EB017F686B</gtr:id><gtr:impact>Generated discussion regarding CPT in NHS and the whole area of Pharmacology within UK</gtr:impact><gtr:outcomeId>568527163361c4.42956364</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>workshop facilitator</gtr:presentationType><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC   Biannual Directors' Meeting.  18th November 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21BAAF32-E345-48DB-B15F-286F52CF16E3</gtr:id><gtr:impact>Information giving wIth colleagues associated with MRC

Continued discussion and dialogue on areas of research that affect/ impact and progress research initiatives</gtr:impact><gtr:outcomeId>564c3ed532a609.70187665</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Statin-induced muscle toxicity: evaluating the functional effects of variability in P450 oxidoreductase (2015) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>783611B4-DA7F-4AFE-B4AA-38DF8F3FF319</gtr:id><gtr:impact>I gave an oral presentation at the University of Liverpool Institute of Translational Medicine Research Day covering my PhD fellowship project rationale and results to date (2015). This led to interesting and productive conversations.

This activity provided publicity for both my project and the MRC fellowship scheme that I am currently enrolled on.</gtr:impact><gtr:outcomeId>58a32723520433.76288479</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic Health Science Networks - Medicines Optimisation Event 26th November 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FAE0B0BB-E2C6-4BCA-AE6C-E406AF47E2E5</gtr:id><gtr:impact>The day is to bring together AHSN teams working on MO to share progress on projects, to solve problems together and to build knowledge; in addition, the day will allow exchange of information with NHS E, ABPI and RPS. Through this we seek to build momentum for change, improve quality of each programme and ensure spread of improvement. There will be breakout sessions including one for those with Patient Safety Collaborative workstreams on medicines.

Safety - including thinking around the collaboratives
Outcomes - including implementing NICE TAs, building a case for use 'value based healthcare'
Patient Experience - including adherence</gtr:impact><gtr:outcomeId>56583cf4106cd3.15221414</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>VII Conference of the Spanish Society of Pharmacogenetics and Pharmacogenomics April  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>45D06846-67F8-4F17-8559-ECA881F66CDF</gtr:id><gtr:impact>Plenary Lecture in the VII Conference of The Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF) 
Talk on &amp;quot;Human genomic variation for personalization of drug treatments, from single genes to the genome-wide era&amp;quot;, 
2-days conference focused on recent progress in pharmacogenetics and pharmacogenomics. Some of the subjects discussed will be:
 
- International projects and new technologies in human genetics
- New advances in pharmacogenomics, consortia and novel working strategies
- Personalization of oncology treatments
- Implementation of pharmacogenetics in the clinic
 

This meeting will include 2 plenary lectures by international renowned experts in the field, 20 invited talks from speakers belonging to different Spanish institutions, and about 120 participants, who will have the opportunity to present their work in poster sessions and, at the discretion of the organisers, give short talks. This format is aimed at facilitating extensive discussion of current issues and at stimulating new ideas. Most presentations will be carried out in Spanish, however, slides will be in English to facilitate discussion.


Human genomic variation for personalization of drug treatments, from single genes to the genome-wide era&amp;quot;, focus of discussion was 
2-days conference focused on recent progress in pharmacogenetics and pharmacogenomics</gtr:impact><gtr:outcomeId>5534f83fe5c062.75963298</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC STRATEGIC OUTLINE  MEETING 6.2.2017</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>14C79A3E-F779-49A6-9C87-706339A8BECA</gtr:id><gtr:impact>Member of MRC EXPERT PANEL</gtr:impact><gtr:outcomeId>58983c0a81c602.75635343</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NWAC  - ALCHOHOL CONFERENCE Liverpool 20th November  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A5760F0E-29D4-40D1-A9AC-B24D842964E4</gtr:id><gtr:impact>Free conference to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines.
 
Discussions is again free to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines.
 
Discussions on the international, national and local perspectives will be supplemented by the showcasing of good practice examples and shared learning from practitioners across the country.
 
NWAC15 provided an unparalleled learning opportunity to exchange thoughts with peers, and build awareness of the range of approaches taken to reduce the harm caused to individuals and communities by alcohol abuse.
 

 


Participant advised that they left with insight which improved their own practice for patients and service users, as well as greater knowledge on how the national agenda is shaping up.</gtr:impact><gtr:outcomeId>564c4df925e1e3.31955770</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Integrating Genetics into Clinical Practice event, Oxford 17th April  2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3035C35A-0231-43BB-BB61-3DE64D553EC1</gtr:id><gtr:impact>Integrating Genetics into Clinical Practice event, Oxford speech tailored to frontline professionals

The 1/2 day event, which will be tailored toward primary care physicians, coverered topics such as the genomics landscape in the UK, the evolution of genetic testing, core competencies in genetics, collaborating with genetic counselors in primary care, as well as the use of pharmacogenomics in primary care.</gtr:impact><gtr:outcomeId>552e7a7ab05576.40555101</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IFCE CONFERENCE PARIS jUNE 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C56E4E1-8C41-45D3-AAF3-D80EA689FDCB</gtr:id><gtr:impact>New Developments in Pharmacogenetics&amp;quot; SPEECH to stimulate thinking

Stimualted thnking amongst those present</gtr:impact><gtr:outcomeId>55892215cc32d2.01620620</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSACI meeting September 2016 -</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B3B1B245-1B6B-459C-8381-58886A84122A</gtr:id><gtr:impact>session title Anaesthetic Allergy
Talk Title: Pharmacogenetics of anaesthetic allergy

increased knowledge from those attending</gtr:impact><gtr:outcomeId>57f38021e5ad99.13354009</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> ICAN Series Conference Paris  December 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>806354AB-437A-4280-934C-F25C0512A039</gtr:id><gtr:impact>Pharmacogenetics in complex human traits title of presentation - sparked discussion and generated new requests for attendance at conferences

further requests for information requested</gtr:impact><gtr:outcomeId>56852542e768b9.75313481</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UPGX MEETING LEIDEN JULY 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>304CFD3C-2376-4922-9790-64218E1EBD4B</gtr:id><gtr:impact>Working group to discuss UPGX protocol</gtr:impact><gtr:outcomeId>577e79503930d5.84353484</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PHARMARELA8 CONFERENCE  February 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>16A7B973-098D-4866-B7CF-FEA011C949E2</gtr:id><gtr:impact>debate on Genomics and therapeutics generated discussion on future direction of genomics and into impact in therapeutics</gtr:impact><gtr:outcomeId>56b86ce8b6aea0.12872981</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint CRN/UK Px &amp; Stratified medicine Network Workshop November 2nd 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A1F7DBD-E33D-45F4-A438-3E77BCE93497</gtr:id><gtr:impact>A Roadmap for Delivery of Stratified Medicine Research in the NHS - the objective of the event is to come up with practical solutions to facilitate the delivery of stratified medicine studies within the NHS with the support of the NIHR CRN.
Key areas covered 
Professor Pirmohamed will provide an overview of the types of challenges associated with the delivery of stratified medicine studies, referring to those identified in the NIHR CRN scoping document (provided in delegate packs) as outlined below;

1 Screening recruits for studies - ensuring resources are available to screen patients and that this activity is recognised. 
2 Cross boundary working where research activity for individual patients occurs at multiple sites, including the need to establish new clinical referral pathways where appropriate
3 Activity recognition (including where activity spans more than one site)
4 Streamlining research management and governance 
5 Access to diagnostic tests and investigations
6 Opportunities and impact of participation in stratified medicine studies for patients 
7 Access to resources to support research activity at all sites 
8 Data management and training (such as eRDC) to support delivery of stratified medicine studies
9 Systems and tools for capturing data for stratified medicine studies
10 Links with other infrastructure (such as ECMCs and CRFs) and feeding into pipeline</gtr:impact><gtr:outcomeId>5819dfa8a4b795.92373240</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC CDSS Drug Repositioning Workshop (Sudeep Pushpakom)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4FB257F6-5BB5-4D38-9DCF-CC4D593FDEF6</gtr:id><gtr:impact>This was a workshop organised at the University of Liverpool under the Centre for Drug Safety Science attended by scientists, academia, pharma industry and regulatory agency representatives where the current status of drug repositioning was discussed.</gtr:impact><gtr:outcomeId>56c49ea98f8922.31938583</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BIG DATA WORKSHOP London 14-15th November  2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7AADB6E8-DA59-4060-9D4D-C122A169E757</gtr:id><gtr:impact>To lead a discussion in the agency and the network of where &amp;quot;Big Data&amp;quot; may have application in medicines development and regulation - a challenging task in terms not only of identifying which data would add the most value but also of when in the life cycle of a medicine it may have the most application. 

talk covered included a case study of genomics in terms of personalised medicine discussing the application of pharmacogenomics across the entire life cycle of a medicine with a forward thinking view on how this could be integrated more routinely into decision making.</gtr:impact><gtr:outcomeId>5829c4eb87da49.75122655</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2016/08/event_detail_001314.jsp&amp;mid=WC0b01ac058004d5c3</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCP advanced medicine conference Feb 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>72F03C9A-FEE7-4095-830E-FB09CAA48DB3</gtr:id><gtr:impact>talked on the topic of 'Important drug interactions' and chaired the session on pharmacology 
The event is a long-running and integral part of the annual RCP conferences programme t is designed to provide advanced medicine training to all physicians and to cover latest cutting-edge advances in clinical practice, underpinned by an improved understanding of the disease mechanism. The conference is one of the RCP's most high-level academic programmes and it's important to present the most cutting-edge scientific advances from across the specialties.</gtr:impact><gtr:outcomeId>56b87124da42d9.86970239</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>84636</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP studentship - 2014</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>97FBAAAD-A89B-445C-87F1-5AB2974D0AEA</gtr:id><gtr:outcomeId>545cfb8922a149.09444229</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The interactions between Clostridium difficile, intestinal microbiota and the host response in hospitalised patients</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1D34B1E4-ADC6-49E8-ADA0-F6A463215D68</gtr:id><gtr:outcomeId>hsMfSB5dWdu</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Liverpool Confidence in Concept Program - Enhancing Translation</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AB9DA0CE-C7BA-4637-A368-596840B9E588</gtr:id><gtr:outcomeId>56f131a370b5b6.74069153</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>239000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROteKT clinical study</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>J P Moulton Charitable Foundation</gtr:fundingOrg><gtr:id>2E953610-579F-44C4-A820-592FA84A8FF7</gtr:id><gtr:outcomeId>546240401b7df9.98912249</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>497130</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Nanoparticle interventions for metastatic cancers - Neil K</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C55939/A21094</gtr:fundingRef><gtr:id>C27E16A7-5403-4879-BA4A-F2AA827D36AC</gtr:id><gtr:outcomeId>56d5849d3cc8f4.37158820</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>647547</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP7 EU funding award (Prediction ADR)</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>602108</gtr:fundingRef><gtr:id>61EDBAA1-47A4-4419-AC7D-601424A6C517</gtr:id><gtr:outcomeId>kevEFLFEK9J</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industry Programme Manager</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Amgen Inc</gtr:fundingOrg><gtr:id>4A1AA3C3-6940-4F8F-9BC5-E6DA2C831B68</gtr:id><gtr:outcomeId>58c928a5261156.67152235</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111147</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>North West Cancer Research project grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:fundingRef>CR986</gtr:fundingRef><gtr:id>E0E6BE7A-D932-4488-A408-B466FAFB3B1F</gtr:id><gtr:outcomeId>BVybfbe9exa</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3052098</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>North West England MRC FELLOWSHIPS in Clinical Pharmacology and Therapeutics</gtr:description><gtr:end>2021-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AEA3AAA9-FECD-404A-967A-0687EAD72E0C</gtr:id><gtr:outcomeId>589865243b8976.10568661</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE studentship -2015 - with Servier</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7732CF8F-F54B-4C69-AA98-AF22E10A76D1</gtr:id><gtr:outcomeId>56d56ba761e696.14726429</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>128968</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NWCR project grant - Ian Copple</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:fundingRef>CR1070</gtr:fundingRef><gtr:id>1FC39FEB-DFC9-480C-A8BD-EFC8431CCBF4</gtr:id><gtr:outcomeId>56d5833979e241.22088307</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000699</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FUTURE initiative</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>University of Liverpool</gtr:fundingOrg><gtr:id>CB0EB3B0-E178-4AF0-9EED-4631CD8C1220</gtr:id><gtr:outcomeId>56f138e01fb138.82703977</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>71427</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drug induced liver injury due to tuberculosis treatment: predictive biomarkers and genetic associations</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Newton Fund</gtr:fundingOrg><gtr:id>9BE95429-BF8E-443B-BCCE-A1072E789EB4</gtr:id><gtr:outcomeId>56f1371142ccd8.34141555</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification of efficacy predictors for clopidogrel using integrated systems pharmacology approach</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Newton Fund</gtr:fundingOrg><gtr:id>B159A764-3E5A-4B7B-B95C-1D4B85202C3E</gtr:id><gtr:outcomeId>56f13781d8b867.56993458</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Applying innovative technologies to improve the benefit-risk ratio of drugs: developing a national resource underpinned by the infrastructure of the MRC Centre for Drug Safety Science</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E5AABA0A-45E5-46BF-9A7D-9D5F365C4F87</gtr:id><gtr:outcomeId>56f1324eccbf67.60103994</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>127327</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE studentship - 2014</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>423076DD-6B23-4DAD-A4F5-88262DC4993D</gtr:id><gtr:outcomeId>545d0520b663f5.29865121</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CDSS DILI Project</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>A3CC289B-DCCE-4BF0-B83F-D5A44488CDAC</gtr:id><gtr:outcomeId>58c925a878b425.96964637</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88210</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC ITTP Studentship -2015</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6C9B83F2-77D3-42CC-97E8-DB1A51FE6D13</gtr:id><gtr:outcomeId>56d56abe670bb7.56439905</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centre for Drug Safety Science - Director</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BD51806B-AD11-49ED-AFF6-3BE3ADEF36A0</gtr:id><gtr:outcomeId>56f129fdde2099.21750100</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25320</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Servier Institute of International Research (IRIS)</gtr:department><gtr:description>Industry Programme Manager</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Servier Laboratories</gtr:fundingOrg><gtr:id>293D097C-3AD1-4D9B-A677-C29B3D26E63B</gtr:id><gtr:outcomeId>58c928fb029d46.18537667</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>368731</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>WEB RADR</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>115632</gtr:fundingRef><gtr:id>0A49CCBE-47CD-4E2F-A8A6-3EFBCF7C3079</gtr:id><gtr:outcomeId>5461fbb2c70681.53173957</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>294002</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR i4i</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>ii-lb-0313-20008</gtr:fundingRef><gtr:id>0557CBFE-D7D8-495D-9E7E-F4B514E7486A</gtr:id><gtr:outcomeId>54620612ebefb9.05840861</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258075</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROteKT - Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis.</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>J P Moulton Charitable Foundation</gtr:fundingOrg><gtr:id>8D2B9DD1-B272-413F-A97A-656DA466E885</gtr:id><gtr:outcomeId>56f12be59bc904.93103697</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>164779</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>An investigation into bosutinib-induced diarrhoea.</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>BD05C4CF-B5C0-4595-8BE2-3A08FDF6060A</gtr:id><gtr:outcomeId>56f13133471655.68190560</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>265000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Application of in vitro cell culture platforms to study the intrinsic immunogenicity of MK3207 and MK0974 - awarded to Dean Naisbitt</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>51D2C231-AF14-4FC9-8793-BEFA3145ED8B</gtr:id><gtr:outcomeId>58c924f37724a2.04683533</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Liverpool Health Partners - Drugs Theme Project Manager</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Liverpool Health Partners</gtr:fundingOrg><gtr:id>A9DC528D-031D-49D7-8551-55C70A599B30</gtr:id><gtr:outcomeId>n5duFsHDuzr</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>Malaysia</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Systems pharmacology approaches to drug-induced hypersensitivity reactions</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Government of Malaysia</gtr:fundingOrg><gtr:id>1D072805-25DE-4BAA-BE4E-C60998106C35</gtr:id><gtr:outcomeId>56f135b54a0b03.84767403</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1078195</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Ubiquitous Pharmacogenomics (UPGX)</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>European Commission H2020</gtr:fundingOrg><gtr:id>4AFE35E7-4B4A-4900-B806-DD2AFF4C4CAB</gtr:id><gtr:outcomeId>589862e182eb67.56002712</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>852700</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>116030</gtr:fundingRef><gtr:id>B951C4C7-F1EB-472D-8EDF-BAB38F0D9999</gtr:id><gtr:outcomeId>58c926642dd860.30824489</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bridging and accelerating the translation of novel scientific findings for health and wealth gain</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>EA3C7B6B-86F6-46F9-94A9-7816929D6F7A</gtr:id><gtr:outcomeId>56f12a7ca1d057.98266684</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury using blood-borne biomarkers CK18 and HMGB1</gtr:description><gtr:grantRef>MR/L006758/1</gtr:grantRef><gtr:id>72D39DF2-F4A1-4C97-86D7-DC33742FD2F7</gtr:id><gtr:impact>Significant publications on the value of using these markers for predicting/detecting DILI in patients</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>Hm8X1eM8BbX</gtr:outcomeId><gtr:patentId>CA2766739</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>METHOD FOR THE DETECTION OF ORGAN OR TISSUE INJURY</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel mechanism-based biomarkers for drug-induced liver injury (HMGB1 and CK18), and methods to measure them.</gtr:description><gtr:grantRef>MR/L006758/1</gtr:grantRef><gtr:id>889B4BCF-F527-4F1E-AF0F-93027AC1DA7A</gtr:id><gtr:impact>None as of yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56b9d0d370ae06.06375581</gtr:outcomeId><gtr:patentId>5721707</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method for the detection of organ or tissue injury</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair of the Pharmacovigilance Expert Advisory Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AC3B1F89-94DB-4AFB-8C5F-18F3B68C535D</gtr:id><gtr:impact>The Pharmacovigilance Expert Advisory Group advises the MHRA through the Commission on Human Medicines on drug safety issues in the UK and in Europe. Advice from the committee can lead to safety updates, restrictions to the use of the drug or occasionally withdrawal of the drug. The work of the committee has impact on every aspect of clinical care in the NHS where drugs are prescribed.</gtr:impact><gtr:outcomeId>jtcYzrF6cBR</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>SJS awareness event launch - House of Commons</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E9BC06C6-647E-45FD-A499-9F0D0456D4EC</gtr:id><gtr:impact>Rt Honorable Margaret Hodge supported the awareness campaign to raise awareness in respect of SJS and the impacts it has on survivors and families - an adjournmment debate will be held in March to support the awarness to assit in new policies at Department of Health being implemented.</gtr:impact><gtr:outcomeId>54d21f432fc410.49209360</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical Pharmacology in the NHS report</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D7C76958-E851-4F0A-9AB3-64A41D3FC268</gtr:id><gtr:outcomeId>5464a0162baee0.46189965</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.bps.ac.uk/details/news/6901701/BPS-Warns-More-Clinical-Pharmacologists-Needed-to-Improve-Health-of-Patients-and.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of the Hepatoxicity SIG Steering Committee (Dan Antoine)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A3816E4C-3A12-4C9A-B791-EEE9938C0F08</gtr:id><gtr:outcomeId>56bc6ba0249fa2.25053367</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical Pharmacology: A dynamic medical specialty essential for UK healthcare</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F070657-7BDE-482E-B5B9-0D7AC657CCF8</gtr:id><gtr:outcomeId>56dc8668bd1cd1.39102693</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Clinical-Pharmacology-A-dynamic-medical-speciality-essential-for-UK-Healthcare.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Re-appointment to Commission on Human Medicines at MHRA for Professor Park</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D376ACF3-1EAF-456D-B16A-CD609DCE7D72</gtr:id><gtr:outcomeId>5460c831e87062.77814733</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Commissioner on Human Medicines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>149B10D6-42BB-4F57-B109-D849C00D3164</gtr:id><gtr:impact>I am Commissoner of Human Medicines, which advises the Secretary of State for Health on drug licesning based on the safety, efficacy and quality of medicines. This has a wide reach and impacts on the use and safety of drugs in the UK and in Europe.</gtr:impact><gtr:outcomeId>ZMFi7Mevj6f</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MEMBER OF 2014/15 quinquennial review (QQR) of the NC3Rs.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>245AD832-C052-4F5A-9C4A-656F529CC29E</gtr:id><gtr:impact>TO advise the MRC and BBSRC on: the effectiveness, quality and impact of the NC3Rs' activities over the past 5 years (2010-2014); the strategic approach and specific plans for the future; and value for money and future allocation of resources.</gtr:impact><gtr:outcomeId>54f97bcc95f937.74127077</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of SCAHT Scientific Advisory Board</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>DFD737C0-276F-4172-ADA5-5F0DC6667C5B</gtr:id><gtr:outcomeId>5460ef21899362.09596552</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Ensuring UK leadership in experimental medicine</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BB6B52CC-96ED-4E2D-A96B-F66FE8561E31</gtr:id><gtr:outcomeId>56dc7e500288c6.78646577</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Assets/Ensuring-UK-leadership-in-experimental-medicine-Aug-2015.pdf?ext=.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The intervention which is tested is Telmisartan, an Angiotensin Receptor Blocker, which is currently used in clinical practice for hypertension. The TAILoR trial is testing Telmisartan for a different indication - to see whether Telmisartin could be effective in reducing insulin resistance in HIV Positive Individuals.</gtr:description><gtr:id>19C2FC98-C58C-40A1-933B-432D0BA4DAF0</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>5461f98faccef7.33288663</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TAILoR</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.tailortrial.org.uk/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>PROteKT is a Phase IIa randomised, controlled trial of Rosuvastatin for the prevention of aminoglycoside-induced Kidney Toxicity in children with cystic fibrosis. It is an example of drug repurposing: utilising a licenced medication for a different indication. It is hoped that this intervention will lead to benefits for children with cystic fibrosis, and to other patients receiving aminoglycoside antibiotics. This is the first human study of rosuvastatin for this indication. The trial received funding from the JP Moulton Foundation, and is currently close to completion of recruitment.</gtr:description><gtr:id>22CE1733-A962-418F-88A8-8D404DC42F7B</gtr:id><gtr:impact>This trial required a suitable, sensitive biomarker of aminoglycoside-induced kidney injury. Current clinical practice relies on change in serum creatinine which is an insensitive marker of early kidney toxicity. Through observational studies we identified a urine biomarker, kidney injury molecule-1, as a promising early marker of aminoglycoside-induced kidney toxicity. Developing and validating this biomarker has allowed us to use this as the primary outcome measure in this study.</gtr:impact><gtr:outcomeId>5461dd0aa04d02.45990452</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PROteKT Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.protekt-trial.org.uk/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>47ECE76F-C167-4CAE-8BB6-F8C565CBDBEB</gtr:id><gtr:title>Pharmacotherapy for alcohol dependence: A stratified approach.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b2e606c7abd26ebb7b86026fa391727"><gtr:id>8b2e606c7abd26ebb7b86026fa391727</gtr:id><gtr:otherNames>Thompson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>55bf7373b62b93.39002286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>273DCC4F-B389-4F7E-8BB2-A7127ED11BE1</gtr:id><gtr:title>Nucleic acid based therapies: developing frontier for precision medicine.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a6b0c1e816896.59086539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC0D6878-512D-423E-A71F-A19BAACD10EE</gtr:id><gtr:title>Target biomarker profile for the clinical management of paracetamol overdose.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b057296e9679837049e61cda42860ace"><gtr:id>b057296e9679837049e61cda42860ace</gtr:id><gtr:otherNames>Vliegenthart AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>56d56627e311e2.31839946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A46E5E9D-3B57-4B6C-9EA1-666D0F3C1702</gtr:id><gtr:title>Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.</gtr:title><gtr:parentPublicationTitle>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0613767e7ae2f6a0e3c4659143859206"><gtr:id>0613767e7ae2f6a0e3c4659143859206</gtr:id><gtr:otherNames>Lewis JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-1552</gtr:issn><gtr:outcomeId>54521892ce7682.11591543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F44BE2A7-D7C1-4469-B67D-404F62534744</gtr:id><gtr:title>ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ec8aa0b4674c8df879b192a3215af5"><gtr:id>72ec8aa0b4674c8df879b192a3215af5</gtr:id><gtr:otherNames>Vijverberg SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>54d36988179259.70283762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92801822-45E4-42A6-AD48-EA032C4E71E8</gtr:id><gtr:title>Through a glass darkly: economics and personalised medicine.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb9b2468962a8352afcf681ca95fd902"><gtr:id>bb9b2468962a8352afcf681ca95fd902</gtr:id><gtr:otherNames>Haycox A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>545213c99ef024.83072064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>805D1C17-06EB-450C-8DBF-2608501A18D0</gtr:id><gtr:title>Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/624bbc02186f52ed82f477482cc2f056"><gtr:id>624bbc02186f52ed82f477482cc2f056</gtr:id><gtr:otherNames>Kim SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5675e4faa48f4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72F44462-5752-4B27-834E-7FB4E75B37FF</gtr:id><gtr:title>Renal function monitoring in heart failure - what is the optimal frequency? A narrative review.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c4a23e93831d40e007b359fba437c5"><gtr:id>d6c4a23e93831d40e007b359fba437c5</gtr:id><gtr:otherNames>Al-Naher A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>59c0de4eb60713.45515641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B9393C-CF31-4555-A048-B72A8FC099FE</gtr:id><gtr:title>Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733c748369e0b187e9271725febc9547"><gtr:id>733c748369e0b187e9271725febc9547</gtr:id><gtr:otherNames>Hawcutt DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>545214734a6da4.89750655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F94F8BF6-DE42-48D9-A5A9-3EA2F177C7D9</gtr:id><gtr:title>From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18b81367b9cdf73b016574a36a182dee"><gtr:id>18b81367b9cdf73b016574a36a182dee</gtr:id><gtr:otherNames>Usui T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>58c7bad5746925.22527460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>385344F6-C2E3-4584-9F7D-ECFAFCE898AF</gtr:id><gtr:title>Genetic variation inpredicts phenytoin-induced maculopapular exanthema in European-descent patients.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e93a8be14f67f13f871370dbb8d62e3"><gtr:id>7e93a8be14f67f13f871370dbb8d62e3</gtr:id><gtr:otherNames>McCormack M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a55dfc5707b30.35420899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84112774-959C-4E4D-B12C-3248277B635A</gtr:id><gtr:title>Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/838882aef57639b670163401a735b461"><gtr:id>838882aef57639b670163401a735b461</gtr:id><gtr:otherNames>Wadelius M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>54521558320861.14186725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2804E9B8-935F-497E-B5D8-557431CEA69B</gtr:id><gtr:title>Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug metabolism &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257900edc4f811b1940f71ebb456c735"><gtr:id>257900edc4f811b1940f71ebb456c735</gtr:id><gtr:otherNames>Sullivan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1742-5255</gtr:issn><gtr:outcomeId>5a995f5558a4d9.34261245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F990B091-3F57-4400-B07D-40812D2C538F</gtr:id><gtr:title>Measures of kidney function by minimally invasive techniques correlate with histological glomerular damage in SCID mice with adriamycin-induced nephropathy.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87eea7b942bb1ad04df38417030dab84"><gtr:id>87eea7b942bb1ad04df38417030dab84</gtr:id><gtr:otherNames>Scarfe L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56cc37cf947987.88449762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51B105E-83AB-487A-8B69-7EF3719BFC8A</gtr:id><gtr:title>UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0db48d5ca75f1d0fdc2698edab0503ac"><gtr:id>0db48d5ca75f1d0fdc2698edab0503ac</gtr:id><gtr:otherNames>Abu-Alainin W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>56d565146b2833.50054139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1F58744-4400-4235-821D-07678C4F2FC6</gtr:id><gtr:title>Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5da6c1c1e4334a7d0a760cacf85564aa"><gtr:id>5da6c1c1e4334a7d0a760cacf85564aa</gtr:id><gtr:otherNames>Pridgeon CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>5aa79779d874f1.82292842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7658E174-3388-43E8-8F25-73DCFA3B6673</gtr:id><gtr:title>Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56d56513c98057.71364879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5C5E8CD-C07C-4EF8-902B-4C2929C092BE</gtr:id><gtr:title>Pharmacogenetic Markers of Drug Efficacy and Toxicity.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>55362713c417b1.19514856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69435E7-1EAA-4975-8138-9451D36E4181</gtr:id><gtr:title>Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae4d1b720139535c8b1235a736c2e9cd"><gtr:id>ae4d1b720139535c8b1235a736c2e9cd</gtr:id><gtr:otherNames>Nattrass R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>5675e27846668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>055F168A-257E-45D8-927E-F6E28050A977</gtr:id><gtr:title>Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ae85010ef2635e8fbe3328a3928243"><gtr:id>34ae85010ef2635e8fbe3328a3928243</gtr:id><gtr:otherNames>Wong MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>585d52c62f6180.83177497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6363986-3FEF-425F-839E-BEC4AE0F3BA7</gtr:id><gtr:title>Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4ab3cb6d0e3c55f6279689b05aa508"><gtr:id>1a4ab3cb6d0e3c55f6279689b05aa508</gtr:id><gtr:otherNames>Bowden DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>5aa79779b253d4.09419747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1A093D1-1531-4E2D-A28C-0C839214980C</gtr:id><gtr:title>The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09be9f4573077df9f08bd4e9b0f22273"><gtr:id>09be9f4573077df9f08bd4e9b0f22273</gtr:id><gtr:otherNames>Sivapalarajah S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5a6885ec8dcb26.40015176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80B4C55C-81FA-493D-A7DD-B13118A2D9D9</gtr:id><gtr:title>Defining drug response for stratified medicine.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/472dd345274de5b0b25b5bcd80367774"><gtr:id>472dd345274de5b0b25b5bcd80367774</gtr:id><gtr:otherNames>Lonergan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>5821f0f7d27ea1.04038198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C64468A6-1D57-4C94-8E55-AB043FF174C1</gtr:id><gtr:title>Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pharmacy and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f96d57f563aea58a8f5662d4f734f1"><gtr:id>03f96d57f563aea58a8f5662d4f734f1</gtr:id><gtr:otherNames>Stewart A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-4727</gtr:issn><gtr:outcomeId>55bf7299e2c036.72166689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C1753CC-9DC5-427A-B3B5-0109DBD737B2</gtr:id><gtr:title>Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a51ca00f999bb332352348602a9c15ef"><gtr:id>a51ca00f999bb332352348602a9c15ef</gtr:id><gtr:otherNames>Mutter FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>56d565143b7a58.68401542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D58A008-0A4A-45B7-B32D-84E11A265098</gtr:id><gtr:title>Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cd73b5befcde04048c06c79fcff11ad"><gtr:id>1cd73b5befcde04048c06c79fcff11ad</gtr:id><gtr:otherNames>Lee KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56d56517228453.83852387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E69337BC-D87D-4D50-9A70-5DC782767243</gtr:id><gtr:title>Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89cbc9f170ee302729639b71bf20ab47"><gtr:id>89cbc9f170ee302729639b71bf20ab47</gtr:id><gtr:otherNames>Sison-Young RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>56d56516545c50.84009882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>080553D6-8FF5-4D20-B0E0-00DE5E426B86</gtr:id><gtr:title>Adrenal responses to a low-dose short synacthen test in children with asthma.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733c748369e0b187e9271725febc9547"><gtr:id>733c748369e0b187e9271725febc9547</gtr:id><gtr:otherNames>Hawcutt DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>547450e28ebb05.80199132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41832C8F-6829-4B09-BBBA-DEB585B2C0D2</gtr:id><gtr:title>Personalized pharmacogenomics: predicting efficacy and adverse drug reactions.</gtr:title><gtr:parentPublicationTitle>Annual review of genomics and human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1527-8204</gtr:issn><gtr:outcomeId>54521558de49a6.35836921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDD879E-3980-418F-98C7-471AD37F1591</gtr:id><gtr:title>The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct V? Receptors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aa797782871b1.03987248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28CE630A-23FE-4822-AA57-94341648B2AD</gtr:id><gtr:title>Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bded6cec3cbccb32e8a38c14ec7d97ba"><gtr:id>bded6cec3cbccb32e8a38c14ec7d97ba</gtr:id><gtr:otherNames>Sutton PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>56d565bd0df353.27842929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F130198-3F63-40D4-8950-1D8D151332B0</gtr:id><gtr:title>Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3bfa3b7807d59b84b48dfd2a1228e74"><gtr:id>e3bfa3b7807d59b84b48dfd2a1228e74</gtr:id><gtr:otherNames>Ogese MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5675de0dc04d7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A35D76C-FD4B-44CE-AC85-FACB72755018</gtr:id><gtr:title>Paracetamol (acetaminophen) poisoning.</gtr:title><gtr:parentPublicationTitle>BMJ clinical evidence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41e0011b97cdcc271473f769dc49182"><gtr:id>b41e0011b97cdcc271473f769dc49182</gtr:id><gtr:otherNames>Park BK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-3846</gtr:issn><gtr:outcomeId>56d565150c81c6.95655650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2514F0C-7B9D-4C9C-ACC8-20CC73F82328</gtr:id><gtr:title>Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>585d3610abccd9.24690740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44F00950-12FC-49FF-B5A3-FB68A80B905B</gtr:id><gtr:title>The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review.</gtr:title><gtr:parentPublicationTitle>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c6a2c83756d3788a29f6e63320cbec2"><gtr:id>6c6a2c83756d3788a29f6e63320cbec2</gtr:id><gtr:otherNames>Lees EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0934-9723</gtr:issn><gtr:outcomeId>57234192319ad4.84018846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46EDBA3B-B1D8-4414-98B3-28E309B17DEF</gtr:id><gtr:title>New Approaches to Investigate Drug-Induced Hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3bfa3b7807d59b84b48dfd2a1228e74"><gtr:id>e3bfa3b7807d59b84b48dfd2a1228e74</gtr:id><gtr:otherNames>Ogese MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>581b2d864f0717.52128812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E33B84BD-2B10-4776-BD6A-05E52F282031</gtr:id><gtr:title>Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a086c46608716c879b38793ef40bdb1d"><gtr:id>a086c46608716c879b38793ef40bdb1d</gtr:id><gtr:otherNames>Johnson GG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>545215585d22f0.78762874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6569CC9D-8812-4E1A-BAF5-CE106BC1A072</gtr:id><gtr:title>Repurposing Statins for Renal Protection: Is It a Class Effect?</gtr:title><gtr:parentPublicationTitle>Clinical and translational science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1752-8054</gtr:issn><gtr:outcomeId>5a14224f693e42.38456784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F00B98C-AA4B-4531-B7E8-EC99C6BE8063</gtr:id><gtr:title>Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18b81367b9cdf73b016574a36a182dee"><gtr:id>18b81367b9cdf73b016574a36a182dee</gtr:id><gtr:otherNames>Usui T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5a8593152c8167.44205767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59BAB9F5-539D-4E18-9CA6-EF32B11E4FE8</gtr:id><gtr:title>Correction: Definition of the Nature and Hapten Threshold of the ?-Lactam Antigen Required for T Cell Activation In Vitro and in Patients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aa79778efe9d3.53149264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBFC32B6-5E16-4C9A-85C0-E32C993520A5</gtr:id><gtr:title>Adrenal responses to a low-dose short synacthen test in children with asthma.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733c748369e0b187e9271725febc9547"><gtr:id>733c748369e0b187e9271725febc9547</gtr:id><gtr:otherNames>Hawcutt DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>570623d694b296.26687516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>584CD2C6-7348-4276-A048-C93D5955F1E2</gtr:id><gtr:title>From mice to men: Murine models of colorectal cancer for use in translational research.</gtr:title><gtr:parentPublicationTitle>Critical reviews in oncology/hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b5b6ff0119b9895306d50637892d6b"><gtr:id>84b5b6ff0119b9895306d50637892d6b</gtr:id><gtr:otherNames>Evans JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1040-8428</gtr:issn><gtr:outcomeId>56d56514107075.88608524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62D6DF27-DB27-4D39-A547-F2BDF1642FB1</gtr:id><gtr:title>Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b145530a1645a0914394554747867e6"><gtr:id>8b145530a1645a0914394554747867e6</gtr:id><gtr:otherNames>Arriazu E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56d566613c3026.74509863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1748D6D7-A3FC-4A03-AD56-AF1BC2B3930A</gtr:id><gtr:title>Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury.</gtr:title><gtr:parentPublicationTitle>Allergy, asthma &amp; immunology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/624bbc02186f52ed82f477482cc2f056"><gtr:id>624bbc02186f52ed82f477482cc2f056</gtr:id><gtr:otherNames>Kim SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2092-7355</gtr:issn><gtr:outcomeId>58c7bad6bcf312.11684390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82B890BD-4B1F-4281-BFA5-193FD35754AB</gtr:id><gtr:title>Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.</gtr:title><gtr:parentPublicationTitle>Diabetes &amp; vascular disease research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1479-1641</gtr:issn><gtr:outcomeId>5a980515014ac4.96751279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00986FA1-C3AD-4372-82F2-C3A503E23C4F</gtr:id><gtr:title>Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73e97dd03451d8d093a5e68f2993f3ff"><gtr:id>73e97dd03451d8d093a5e68f2993f3ff</gtr:id><gtr:otherNames>Eakins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56b9bdee641ba3.43158875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB0BC478-E7DD-4726-9703-B067463BD0DC</gtr:id><gtr:title>Achieving the World Health Organization's vision for clinical pharmacology.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5626445be489cc30af426175486aac60"><gtr:id>5626445be489cc30af426175486aac60</gtr:id><gtr:otherNames>Martin JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>5620d0b5953ec7.04466506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFA80A5C-F63E-4E8C-9C3B-66B782EBF5F2</gtr:id><gtr:title>Management of allergy to penicillins and other beta-lactams.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b73e01f0a849395586da3fdedf61447"><gtr:id>2b73e01f0a849395586da3fdedf61447</gtr:id><gtr:otherNames>Mirakian R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>55bf7450412109.38127461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B4721D6-09F3-496E-84C5-49190BDD28D5</gtr:id><gtr:title>Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC-MS/MS method.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7c3fe5d8ec9f343325d0281d8282f13"><gtr:id>c7c3fe5d8ec9f343325d0281d8282f13</gtr:id><gtr:otherNames>Rodrigues AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>545216f6dd96c4.86131032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5C8F9FB-BE54-4BFD-93DA-052CE4ACF0A6</gtr:id><gtr:title>The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/023879f3cd728bfa9bfa1cd2ad34be63"><gtr:id>023879f3cd728bfa9bfa1cd2ad34be63</gtr:id><gtr:otherNames>Giannoudis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>545219a1761c71.29662921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6254A5D1-7568-41AD-8201-01320A58A93B</gtr:id><gtr:title>Personalized medicine approaches in epilepsy.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>5450d1d72221f2.23177688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6D885FD-EB62-4BDB-8865-ADCD4BE6B5A0</gtr:id><gtr:title>Trimethoprim-induced aseptic meningism.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e584200b8b6a0ee2f29358ed5173745"><gtr:id>5e584200b8b6a0ee2f29358ed5173745</gtr:id><gtr:otherNames>Lochlainn MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>58c7bb8fa4a1d2.05755562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41520F51-0291-4685-BC93-B87D850A0208</gtr:id><gtr:title>Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9938df0bfdfb500f731f17be25c08d8"><gtr:id>f9938df0bfdfb500f731f17be25c08d8</gtr:id><gtr:otherNames>Sabbisetti VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5460edd7de41d5.67820069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC7A0FC8-3C6C-41C1-A1CA-5D066142E571</gtr:id><gtr:title>Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92441bf120a5c93300425e13f76d301c"><gtr:id>92441bf120a5c93300425e13f76d301c</gtr:id><gtr:otherNames>Bedson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>54521472ea0c44.30992553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AC7FE4A-134B-4387-9A2D-B4C53ED45D2A</gtr:id><gtr:title>Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d53a3afd301c96535e58f4eb19ac9f4c"><gtr:id>d53a3afd301c96535e58f4eb19ac9f4c</gtr:id><gtr:otherNames>Heslop JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>doi_55f98498465b34c0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46CA595D-7DE6-49E6-B539-FB9F30CE3FE5</gtr:id><gtr:title>Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.</gtr:title><gtr:parentPublicationTitle>Alcohol (Fayetteville, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bd65b7cb9b04d90406706c2e48650ee"><gtr:id>2bd65b7cb9b04d90406706c2e48650ee</gtr:id><gtr:otherNames>Whitfield JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0741-8329</gtr:issn><gtr:outcomeId>5a55df97efe3c2.20091604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A1F3CD0-10E0-42C0-92D2-35C6C7B22F7F</gtr:id><gtr:title>MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa09d749322a0ec9a702c584968cf0a7"><gtr:id>aa09d749322a0ec9a702c584968cf0a7</gtr:id><gtr:otherNames>Howell LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5aa7977a107c07.38863710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF0D573C-3F11-4FF3-BE3E-3907AC96A622</gtr:id><gtr:title>Where are we now with paracetamol?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0657e0f67428a9fd42aaeab3b2c965da"><gtr:id>0657e0f67428a9fd42aaeab3b2c965da</gtr:id><gtr:otherNames>Dear JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>56d565161e0df1.62726605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7612868A-3802-41E4-8D25-584193A9ACB8</gtr:id><gtr:title>Effect of Genetic Variability in the,, andGenes on Liver mRNA Levels and Warfarin Response.</gtr:title><gtr:parentPublicationTitle>Frontiers in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b56f14721276feb5de13d37a7165def6"><gtr:id>b56f14721276feb5de13d37a7165def6</gtr:id><gtr:otherNames>Zhang JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1663-9812</gtr:issn><gtr:outcomeId>5947d8869905d5.58294840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDBE8FEC-0842-433D-8639-52EAE827ED40</gtr:id><gtr:title>Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37003dae6da11365d2de17053c3fcf50"><gtr:id>37003dae6da11365d2de17053c3fcf50</gtr:id><gtr:otherNames>Barber JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>56b9bc74403fb5.45879882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A2FAA49-1836-4A85-B5AF-3058B1EB56A3</gtr:id><gtr:title>Theallele: influence on carbamazepine treatment.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics and personalized medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1178-7066</gtr:issn><gtr:outcomeId>58a1b3be16b0b0.38478704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49F38D5-4863-42CA-917E-E55AF8B18E2A</gtr:id><gtr:title>Genomics of Adverse Drug Reactions.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>586a2424a746e4.03640641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C7D4BD4-3019-4ED7-AB6F-68DBECB2C627</gtr:id><gtr:title>Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b37ca4a49d0616af26ea31242e516956"><gtr:id>b37ca4a49d0616af26ea31242e516956</gtr:id><gtr:otherNames>Pink J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>54521c733569e9.39553330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>022355E9-CE0E-4688-A5FD-BC7D63E4C4D3</gtr:id><gtr:title>SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.</gtr:title><gtr:parentPublicationTitle>The journal of allergy and clinical immunology. In practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/105134d04e84642e6c5580252452f6d2"><gtr:id>105134d04e84642e6c5580252452f6d2</gtr:id><gtr:otherNames>White KD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a55e0f1598e88.84890816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B8AB0D-8C85-473C-8194-617C51F93311</gtr:id><gtr:title>The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Human &amp; experimental toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ea2afe006676f0dfecef58ed9d73a27"><gtr:id>7ea2afe006676f0dfecef58ed9d73a27</gtr:id><gtr:otherNames>Tailor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-3271</gtr:issn><gtr:outcomeId>56d565136f5262.60398573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27E0F2B0-050F-405A-8420-07D4F3B3CD10</gtr:id><gtr:title>CYP2B6 c.983T&amp;gt;C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>545213c972f3c8.27154066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9FA243B-86CA-4AA5-949B-BD6D7BC63850</gtr:id><gtr:title>Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3bfa3b7807d59b84b48dfd2a1228e74"><gtr:id>e3bfa3b7807d59b84b48dfd2a1228e74</gtr:id><gtr:otherNames>Ogese MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>5aa797786580a3.40881758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6611043-706A-4A2F-A77E-BA73DA5AD24F</gtr:id><gtr:title>New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>55cafb5f606110.93975097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8395E5C-9AB1-4188-96A5-BD25F317048B</gtr:id><gtr:title>Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>55950eabc14ba6.23794628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B16C624C-50BF-4BEE-B09A-BB3E100FF917</gtr:id><gtr:title>PAEDIATRIC ADVERSE DRUG REACTIONS (ADRS): A COMPARISON OF A NEWLY DEVELOPED AVOIDABILITY TOOL TO EXISTING HALLAS ASSESSMENTS.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/210e5d8af4d14857840101303855ceac"><gtr:id>210e5d8af4d14857840101303855ceac</gtr:id><gtr:otherNames>Bracken L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>57bda6b7afa4d0.06179663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D69DA69E-7AF5-475B-A87A-53F4512E0D2E</gtr:id><gtr:title>Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b057296e9679837049e61cda42860ace"><gtr:id>b057296e9679837049e61cda42860ace</gtr:id><gtr:otherNames>Vliegenthart AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d56514d22c57.44818426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37F6BF36-D8B3-4D08-9417-EDBC4882B554</gtr:id><gtr:title>Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a560bbf813d4b89e7ed84fd366393c7"><gtr:id>1a560bbf813d4b89e7ed84fd366393c7</gtr:id><gtr:otherNames>Felgner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>5950f1cda62ac6.59712315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>702C9B2D-43FB-4C39-AB39-C23ECEF6226D</gtr:id><gtr:title>Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36397f502012809ce2e57a15f28eec2c"><gtr:id>36397f502012809ce2e57a15f28eec2c</gtr:id><gtr:otherNames>Amali MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>5aa79777e0f990.59955212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F733870-D724-4B89-9717-7B443E383DF3</gtr:id><gtr:title>A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/251e8f80dc64f3415ad91ed03022c666"><gtr:id>251e8f80dc64f3415ad91ed03022c666</gtr:id><gtr:otherNames>Plumpton CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>56f161a78b6547.04548147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>527AAEE1-DEAE-45E5-9AA3-834BFC068498</gtr:id><gtr:title>Biomarkers of adverse drug reactions.</gtr:title><gtr:parentPublicationTitle>Experimental biology and medicine (Maywood, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1535-3699</gtr:issn><gtr:outcomeId>59ccf1bee3fd35.90573962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F5A40D5-AFC0-45F9-B746-96871011009E</gtr:id><gtr:title>A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110a5a15cdf4ecd625897683299baf77"><gtr:id>110a5a15cdf4ecd625897683299baf77</gtr:id><gtr:otherNames>Lundb?ck P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a360fdca77258.70092845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07777BB2-7881-4A04-89B6-60A25F5B5A11</gtr:id><gtr:title>Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>British journal of anaesthesia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c81b4194ebf8d03fdac08d0cba2b302"><gtr:id>8c81b4194ebf8d03fdac08d0cba2b302</gtr:id><gtr:otherNames>Bellis JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0912</gtr:issn><gtr:outcomeId>545215588af3a3.17357540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B6C0034-D617-4C66-AAD0-E2B3142C2AE0</gtr:id><gtr:title>Advances in the Pharmacogenomics of Adverse Drug Reactions.</gtr:title><gtr:parentPublicationTitle>Drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb81aa1d4a36387abc93c9841d80e769"><gtr:id>eb81aa1d4a36387abc93c9841d80e769</gtr:id><gtr:otherNames>Collins SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0114-5916</gtr:issn><gtr:outcomeId>568521ac8c4a45.78663892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3431A563-E43B-42EC-AAEB-C87CDD474411</gtr:id><gtr:title>Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8425919480c9465c744e1eee5124520"><gtr:id>e8425919480c9465c744e1eee5124520</gtr:id><gtr:otherNames>Goldstein JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>545212d2ee3b28.88332152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB5D158E-860C-46E5-B939-A39DB7E9F7C0</gtr:id><gtr:title>How to treat paracetamol overdose and when to do it.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1751-2433</gtr:issn><gtr:outcomeId>56d5666110efc5.74129890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F34DECE3-51DC-4323-946F-D1AC4CABEFA5</gtr:id><gtr:title>Drug-specific CD4T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fc671a577855d4f3c8e024a8454b0f6"><gtr:id>8fc671a577855d4f3c8e024a8454b0f6</gtr:id><gtr:otherNames>Ye YM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>58c7bad68b35c4.28994661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DBD729C-96CA-4A2A-B437-3407BD50EFFE</gtr:id><gtr:title>Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8cd6a8c145d14880ed2be9c7057023"><gtr:id>6e8cd6a8c145d14880ed2be9c7057023</gtr:id><gtr:otherNames>Martin MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>545218933f35a6.14647248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>748A1439-13A8-45A7-96CA-FEBC18E2F9EC</gtr:id><gtr:title>Treatment of paracetamol overdose: room for improvement?</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d34752719f97437dbb7201d5dea68994"><gtr:id>d34752719f97437dbb7201d5dea68994</gtr:id><gtr:otherNames>Park K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>545219a1d27076.40942050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97E1F3FD-775A-49AE-BF33-77F572EAC2B7</gtr:id><gtr:title>Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c35a6c3675f72acf743d0080b0484ad3"><gtr:id>c35a6c3675f72acf743d0080b0484ad3</gtr:id><gtr:otherNames>Ravenscroft SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>585d66b9741200.02446065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>742A6067-52C3-4210-A45D-1D725BA82165</gtr:id><gtr:title>Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of
 
 Models</gtr:title><gtr:parentPublicationTitle>Applied In Vitro Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f098469dc1dbb18dc75ff4bb9372c1b"><gtr:id>7f098469dc1dbb18dc75ff4bb9372c1b</gtr:id><gtr:otherNames>Goldring C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56b9c15a86c036.00843520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B772DE9-4ABA-4718-9948-C3AC386E0992</gtr:id><gtr:title>Patients benefit from genetics-guided coumarin anticoagulant therapy.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e52efabd2158524dc3527f11f0a0786"><gtr:id>9e52efabd2158524dc3527f11f0a0786</gtr:id><gtr:otherNames>Maitland-van der Zee AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>54521558b3c030.80728900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58702F5E-3D20-4ECA-84A0-F80E2BA12017</gtr:id><gtr:title>Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/784434facbd8f27bc51eeec81a865dba"><gtr:id>784434facbd8f27bc51eeec81a865dba</gtr:id><gtr:otherNames>Belley-Cote EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>55af9af1e42472.12170995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3186EAE-561B-4EC5-BC7B-6AAFFDD3A5E5</gtr:id><gtr:title>Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c81b4194ebf8d03fdac08d0cba2b302"><gtr:id>8c81b4194ebf8d03fdac08d0cba2b302</gtr:id><gtr:otherNames>Bellis JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>54521c73878ac2.39416365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A316E202-B835-47DA-AF67-0878440A916B</gtr:id><gtr:title>Real-time in vivo imaging reveals localised Nrf2 stress responses associated with direct and metabolism-dependent drug toxicity.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc2d8d91bf879d884ccff7f7d338a070"><gtr:id>dc2d8d91bf879d884ccff7f7d338a070</gtr:id><gtr:otherNames>Forootan SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa797794e86a4.77340860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4758A48-BE38-4B18-914F-015358FD4B56</gtr:id><gtr:title>An integrative in silico system for predicting dysregulated genes in the human epileptic focus: Application to SLC transporters.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc61108dcb0a8fa8c9f0c853337c0fa0"><gtr:id>fc61108dcb0a8fa8c9f0c853337c0fa0</gtr:id><gtr:otherNames>Mirza N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5795c40eb7a5b4.20435884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9593AD75-6A1A-4518-90CC-D442B8F84EC0</gtr:id><gtr:title>Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>European journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c3ab0b16ccd354a403092ea5545c0be"><gtr:id>0c3ab0b16ccd354a403092ea5545c0be</gtr:id><gtr:otherNames>Govindappa K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-6970</gtr:issn><gtr:outcomeId>55d584d86fc7b5.68933310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>788DA5B2-3721-4B91-901B-654192C25FDD</gtr:id><gtr:title>DAMP signaling is a key pathway inducing immune modulation after brain injury.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/838d14d2ee0664a7c1b3b453d065bc64"><gtr:id>838d14d2ee0664a7c1b3b453d065bc64</gtr:id><gtr:otherNames>Liesz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56d5662823f1f8.11797263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79E58C68-1967-4F79-B1C8-713AD34336BD</gtr:id><gtr:title>Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group.</gtr:title><gtr:parentPublicationTitle>JAMA dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4ed5b649ccc38c99f3f761ab9392818"><gtr:id>e4ed5b649ccc38c99f3f761ab9392818</gtr:id><gtr:otherNames>Maverakis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-6068</gtr:issn><gtr:outcomeId>58d253ebe3fb80.76457152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CFD4EC5-FCAC-4DA1-BE0A-FA51334C313C</gtr:id><gtr:title>Roles of Nrf2 in drug and chemical toxicity</gtr:title><gtr:parentPublicationTitle>Current Opinion in Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bde731ec668d4a9d960163b07955ad2d"><gtr:id>bde731ec668d4a9d960163b07955ad2d</gtr:id><gtr:otherNames>Clarke J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d340d379ed1.87738280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>086A051B-7309-45E1-9A6E-38E27FAC1AD6</gtr:id><gtr:title>Towards the development of mechanism-based biomarkers to diagnose drug hypersensitivity</gtr:title><gtr:parentPublicationTitle>Toxicology Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1478f390ef910270329f824a5a7eb6db"><gtr:id>1478f390ef910270329f824a5a7eb6db</gtr:id><gtr:otherNames>Duran-Figueroa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56b9b1d526d553.57305292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D98A718C-048E-4377-97A3-762F83212C0E</gtr:id><gtr:title>Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>58904e09690a53.76762715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E747A5A-4258-469F-8F21-6D981AB73E95</gtr:id><gtr:title>HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/369a7b3b1cfaf21e69bc0b37d13ae9d6"><gtr:id>369a7b3b1cfaf21e69bc0b37d13ae9d6</gtr:id><gtr:otherNames>Napolitano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56d566617dbe66.98835575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67CC38E8-2C34-46FF-A555-AE53B793462A</gtr:id><gtr:title>Social media and pharmacovigilance: A review of the opportunities and challenges.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b22f708e15e1874a8f722f0c602aea55"><gtr:id>b22f708e15e1874a8f722f0c602aea55</gtr:id><gtr:otherNames>Sloane R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>55a38dba183d51.26750004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9F1DCBE-CB30-4C6A-8869-7D036189B1D3</gtr:id><gtr:title>Correction: The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct V? Receptors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aa79779225660.03810153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58A7AA25-114F-494F-832E-945849BC931F</gtr:id><gtr:title>Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca30cc0ad8c0f95e3c2b7f9bad321798"><gtr:id>ca30cc0ad8c0f95e3c2b7f9bad321798</gtr:id><gtr:otherNames>Shelton LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>56d565153ef442.09172817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B938EA21-5358-43AE-8D01-2654DFD72109</gtr:id><gtr:title>?-Lactam hypersensitivity involves expansion of circulating and skin-resident T22&amp;nbsp;cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257900edc4f811b1940f71ebb456c735"><gtr:id>257900edc4f811b1940f71ebb456c735</gtr:id><gtr:otherNames>Sullivan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58c7bb8f76a715.39345726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5803ED17-2DDD-4EAE-8FEB-C29232303F82</gtr:id><gtr:title>Phenotype standardization for statin-induced myotoxicity.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>545216f6915879.60248565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E87646CD-876E-4D5B-AEA1-768534CF6EEF</gtr:id><gtr:title>Health-Economic Evaluation of Clostridium Difficile Infection (Cdi) And Epidemiology In England And Merseyside.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10f031052d961e069f64ecd0d6adbe4d"><gtr:id>10f031052d961e069f64ecd0d6adbe4d</gtr:id><gtr:otherNames>Nakamura CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>563c8b63144ce2.12789370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7107EB25-8AEB-4F37-AD6A-B841BB28F05C</gtr:id><gtr:title>Validation of a multigenic model to predict seizure control in newly treated epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsy research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72151ae8f0403d5e6d3cdf20e7db22a4"><gtr:id>72151ae8f0403d5e6d3cdf20e7db22a4</gtr:id><gtr:otherNames>Shazadi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0920-1211</gtr:issn><gtr:outcomeId>5450d2e96c1781.08067397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D32DC651-268C-4A76-A963-E3F22745A092</gtr:id><gtr:title>Redox-Dependent HMGB1 Isoforms as Pivotal Co-Ordinators of Drug-Induced Liver Injury: Mechanistic Biomarkers and Therapeutic Targets.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69d55306df27bff0617a6d1a234578a8"><gtr:id>69d55306df27bff0617a6d1a234578a8</gtr:id><gtr:otherNames>Lea JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>56d56627b1f792.73729150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FE51B62-D536-4A30-B786-1B5EDE2E61B2</gtr:id><gtr:title>Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>54521c730d1747.73346674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A96C36B9-762E-42FD-B7DA-E3D100F1E399</gtr:id><gtr:title>Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18b81367b9cdf73b016574a36a182dee"><gtr:id>18b81367b9cdf73b016574a36a182dee</gtr:id><gtr:otherNames>Usui T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>58c7bad4c16726.70963569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1920715F-D74E-4CF5-8056-D51A07543A78</gtr:id><gtr:title>Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de7f9b00b89b6585714aaf6bb96edf01"><gtr:id>de7f9b00b89b6585714aaf6bb96edf01</gtr:id><gtr:otherNames>Marvig CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>5555c74054c850.90565963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F400420-0F0A-40F6-A122-45C5D41A483A</gtr:id><gtr:title>N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.</gtr:title><gtr:parentPublicationTitle>European journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/526ce99e8aae11381b46a836d1daa026"><gtr:id>526ce99e8aae11381b46a836d1daa026</gtr:id><gtr:otherNames>Ng CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-6970</gtr:issn><gtr:outcomeId>545216f6b8e132.47999093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E4280B0-4D45-41D5-B715-9B9CE76484CB</gtr:id><gtr:title>Optimising the use of medicines to reduce acute kidney injury in children and babies.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c59e7c89cf935ba8559cf2dfe38b2bef"><gtr:id>c59e7c89cf935ba8559cf2dfe38b2bef</gtr:id><gtr:otherNames>Oni L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>5aa797797e2cf5.99941712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72B5C91D-F67F-49A6-B6B0-1E8C52897518</gtr:id><gtr:title>HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc09024bc44f267fc9eac5bed53d2bf8"><gtr:id>dc09024bc44f267fc9eac5bed53d2bf8</gtr:id><gtr:otherNames>Cheung CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>565839ea6564e5.80560057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A783BC-D63E-4064-BE1D-6DABD20C271D</gtr:id><gtr:title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e065a2e25883eddb8591f75c6e35df"><gtr:id>68e065a2e25883eddb8591f75c6e35df</gtr:id><gtr:otherNames>Johnson JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>58a6e54fb6b5c4.77314449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>174A9E99-858E-46AA-9920-C6785FD75B5A</gtr:id><gtr:title>Cardiovascular pharmacogenomics: expectations and practical benefits.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4469eb28365ff976201c153df829a59"><gtr:id>b4469eb28365ff976201c153df829a59</gtr:id><gtr:otherNames>Turner RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>545219a1aa3379.83588197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D653176-018F-4A02-B3B9-3DDA37691E9B</gtr:id><gtr:title>Progress in pharmacogenetics: consortiums and new strategies.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and personalized therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b48fe6bdb409fdd002ad571691af05b9"><gtr:id>b48fe6bdb409fdd002ad571691af05b9</gtr:id><gtr:otherNames>Maro?as O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2363-8915</gtr:issn><gtr:outcomeId>56d45bb8ba6e07.43584306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43563D45-52ED-4EE3-BB7B-0B8C9A8A06A3</gtr:id><gtr:title>Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d53a3afd301c96535e58f4eb19ac9f4c"><gtr:id>d53a3afd301c96535e58f4eb19ac9f4c</gtr:id><gtr:otherNames>Heslop JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>5a54ec4b386be5.74905662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B8D553A-60D1-4A45-B2AD-3716AC4B031D</gtr:id><gtr:title>A common missense variant of LILRB5 is associated with statin intolerance and myalgia.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cbd2f93107cdf857f5b1d5cff5c4389"><gtr:id>6cbd2f93107cdf857f5b1d5cff5c4389</gtr:id><gtr:otherNames>K Siddiqui M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>59e09aa6dea191.14875256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C7E90C3-39D0-495C-9C9D-B97879F3C130</gtr:id><gtr:title>MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>doi_55f9849846407382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF1C10DA-B44B-47CF-A174-56D922CED36B</gtr:id><gtr:title>Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e875e1050196c8d029bc61e171597736"><gtr:id>e875e1050196c8d029bc61e171597736</gtr:id><gtr:otherNames>Antoine DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56b9b7e1ed2c15.39978524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B27F0742-5089-450A-A7C9-AB49C46929DA</gtr:id><gtr:title>Identification of drug- and drug-metabolite immune responses originating from both naive and memory T cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58c7bb8fcfc457.62458450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08B06195-7906-4182-9349-289770B37E3C</gtr:id><gtr:title>Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5922c99aa59a96.84892041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B3F4978-FE5A-4C8F-BBDC-1220ED6AE052</gtr:id><gtr:title>Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d19dd5a51d1cf4ff43003c1c9e4cf808"><gtr:id>d19dd5a51d1cf4ff43003c1c9e4cf808</gtr:id><gtr:otherNames>Naisbitt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d5651572e037.31398763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E2E6E31-3E69-4910-8042-A0E7BFC486BE</gtr:id><gtr:title>Genotype-guided dosing of vitamin K antagonists.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>545216f7131736.03691108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1295E2D-7869-4566-9E03-9B2A01556411</gtr:id><gtr:title>Pediatric microdose and microtracer studies using 14C in Europe.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97c3228c7e6bdf78b083d1cfbc2d2d9b"><gtr:id>97c3228c7e6bdf78b083d1cfbc2d2d9b</gtr:id><gtr:otherNames>Turner MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>56b9b9b9757cc0.40069131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CE0B88C-221E-4487-B848-85E2B4EF2108</gtr:id><gtr:title>Correction: The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct V? Receptors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5a82a18c4a9b24.94195851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D57C0D9C-D17A-4921-9558-591A2B422B74</gtr:id><gtr:title>Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/406bc16bb7439f5acb889c12717fa178"><gtr:id>406bc16bb7439f5acb889c12717fa178</gtr:id><gtr:otherNames>Verhoef TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>57a461847aa461.24360214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1924C0F-A57A-48C5-B9B3-ECB76352F0C8</gtr:id><gtr:title>A review of a priori regression models for warfarin maintenance dose prediction.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fa7baed41e41d46127e14afeeaeb7b4"><gtr:id>7fa7baed41e41d46127e14afeeaeb7b4</gtr:id><gtr:otherNames>Francis B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54b7950ec1fd42.99133817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1B59E6F-FCE3-4EBE-8190-C3E9DF2EFC6D</gtr:id><gtr:title>Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc61108dcb0a8fa8c9f0c853337c0fa0"><gtr:id>fc61108dcb0a8fa8c9f0c853337c0fa0</gtr:id><gtr:otherNames>Mirza N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>554b1b24dcf711.56780927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>038B6DCE-53DE-4147-AA27-720D52327EC6</gtr:id><gtr:title>MD-2 is required for disulfide HMGB1-dependent TLR4 signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>56d566285a25a9.11023990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CC02332-415B-4459-BE76-86422FE22756</gtr:id><gtr:title>Parsing interindividual drug variability: an emerging role for systems pharmacology.</gtr:title><gtr:parentPublicationTitle>Wiley interdisciplinary reviews. Systems biology and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4469eb28365ff976201c153df829a59"><gtr:id>b4469eb28365ff976201c153df829a59</gtr:id><gtr:otherNames>Turner RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1939-005X</gtr:issn><gtr:outcomeId>5555c6f8148782.18568646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D88C3B64-5B8C-4EDD-8EC8-7AD4A9F9BECF</gtr:id><gtr:title>Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug metabolism &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257900edc4f811b1940f71ebb456c735"><gtr:id>257900edc4f811b1940f71ebb456c735</gtr:id><gtr:otherNames>Sullivan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1742-5255</gtr:issn><gtr:outcomeId>5aa79778c19280.24197534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAE8BC28-209F-4821-869A-113DD9CA12CC</gtr:id><gtr:title>How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?</gtr:title><gtr:parentPublicationTitle>European journal of obstetrics, gynecology, and reproductive biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a450c213d088c33aeaa288d415feab15"><gtr:id>a450c213d088c33aeaa288d415feab15</gtr:id><gtr:otherNames>Navaratnam K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0301-2115</gtr:issn><gtr:outcomeId>59e09b0592ae40.83450482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C34CD71-0DC3-45FD-8C9B-B36AAF9E1795</gtr:id><gtr:title>Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ee0548ea9f20fc8585fef80f1dc5f05"><gtr:id>7ee0548ea9f20fc8585fef80f1dc5f05</gtr:id><gtr:otherNames>Thulin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>doi_55f98498464942e0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B20ACBCC-D8CF-48EF-B994-B2E2ECFE9DEF</gtr:id><gtr:title>Is the interleukin 8 promoter polymorphism rs4073/-251T &amp;gt;A associated with Clostridium difficile infection?</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/482d3b2888688e6d089b959ec62e3143"><gtr:id>482d3b2888688e6d089b959ec62e3143</gtr:id><gtr:otherNames>Miyajima F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>545217cc01a0b8.20368408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91180F19-F780-487A-B307-FCA2DDD23B5E</gtr:id><gtr:title>Pharmacogenomics: Current State-of-the-Art.</gtr:title><gtr:parentPublicationTitle>Genes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2073-4425</gtr:issn><gtr:outcomeId>54006690c681c8.74735866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEC4D67C-5391-4DAA-8760-0C54D2BDD995</gtr:id><gtr:title>Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5875dca3e87b43.65242060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A026BEED-35CC-49DC-926A-71780E0305E9</gtr:id><gtr:title>Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2d9fa1a88f103697110ef54a94e06f0"><gtr:id>a2d9fa1a88f103697110ef54a94e06f0</gtr:id><gtr:otherNames>Faulkner L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>57e13e8ad27d08.47533578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0C31E2B-F438-44B6-BD76-70B76721C89C</gtr:id><gtr:title>Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d53a3afd301c96535e58f4eb19ac9f4c"><gtr:id>d53a3afd301c96535e58f4eb19ac9f4c</gtr:id><gtr:otherNames>Heslop JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>58a315c6cdc322.28108949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>159B5501-EE38-420D-8E2C-4E47409BE528</gtr:id><gtr:title>MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa09d749322a0ec9a702c584968cf0a7"><gtr:id>aa09d749322a0ec9a702c584968cf0a7</gtr:id><gtr:otherNames>Howell LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5a3518e126a256.85415912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C13F19FC-106A-456F-84B7-7DDA32143F6D</gtr:id><gtr:title>Exploring the translational disconnect between the murine and human inflammatory response: analysis of LPS dose-response relationship in murine versus human cell lines and implications for translation into murine models of sepsis.</gtr:title><gtr:parentPublicationTitle>Journal of inflammation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea9744ddd1145a5b8c47b671348c0ad9"><gtr:id>ea9744ddd1145a5b8c47b671348c0ad9</gtr:id><gtr:otherNames>McCarron EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1178-7031</gtr:issn><gtr:outcomeId>56d5662777be10.56823566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCE7A490-5801-4340-9EDB-EEDCCC002144</gtr:id><gtr:title>Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f6e2b589637133576bc99ec570b25b"><gtr:id>e8f6e2b589637133576bc99ec570b25b</gtr:id><gtr:otherNames>Kumar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>568521ac65e706.67967817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A0A1446-F78B-4395-A0D3-43B075AA5E80</gtr:id><gtr:title>Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6839b5a23077614d6e869d26e333995"><gtr:id>a6839b5a23077614d6e869d26e333995</gtr:id><gtr:otherNames>Phillips EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>5a784af8c26722.01801575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9764D98D-C805-4167-ABE1-0A199A5F52D8</gtr:id><gtr:title>Statins, immunomodulation, and infections: a complex and unresolved relationship.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>545219a2015f59.07951667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062DD0DA-35FE-42BB-AF69-333CFBCD65FC</gtr:id><gtr:title>Clinical coding of prospectively identified paediatric adverse drug reactions--a retrospective review of patient records.</gtr:title><gtr:parentPublicationTitle>BMC pharmacology &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c81b4194ebf8d03fdac08d0cba2b302"><gtr:id>8c81b4194ebf8d03fdac08d0cba2b302</gtr:id><gtr:otherNames>Bellis JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-6511</gtr:issn><gtr:outcomeId>54b794a12117a3.07787783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>752B4194-82D9-4CC5-9F70-DD68EE2612EE</gtr:id><gtr:title>A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality.</gtr:title><gtr:parentPublicationTitle>The International journal of pharmacy practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a328dde90a8c07550067687ea668cc31"><gtr:id>a328dde90a8c07550067687ea668cc31</gtr:id><gtr:otherNames>Conroy EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0961-7671</gtr:issn><gtr:outcomeId>5577e0e1f2be96.12023956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD0686FF-73E7-41E7-8F3A-E7B61AFED47F</gtr:id><gtr:title>Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.</gtr:title><gtr:parentPublicationTitle>Toxicology and applied pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b35ce3a3b74ea6150b12eeb0a36050c"><gtr:id>3b35ce3a3b74ea6150b12eeb0a36050c</gtr:id><gtr:otherNames>Woolbright BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0041-008X</gtr:issn><gtr:outcomeId>doi_55faa1aa1c85fda2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480A8CE7-9A46-41A5-A73A-FAE2770725E2</gtr:id><gtr:title>Identifying cisplatin-induced kidney damage in paediatric oncology patients.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8db7961fc9b624538ea714451b21837"><gtr:id>a8db7961fc9b624538ea714451b21837</gtr:id><gtr:otherNames>Barton CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>599c2deacd17a7.05476920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F442B1D7-AAEB-46C2-9755-52009B03F6BF</gtr:id><gtr:title>Aminoglycoside-induced nephrotoxicity in children.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>583409f36aa7d3.66965489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99D21DD6-0394-4675-B629-1C9DF3FB9F8E</gtr:id><gtr:title>Detection of drug-responsive B lymphocytes and antidrug IgG in patients with ?-lactam hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36397f502012809ce2e57a15f28eec2c"><gtr:id>36397f502012809ce2e57a15f28eec2c</gtr:id><gtr:otherNames>Amali MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>58c7bad4e4ea87.75324308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CD6305F-555D-4C92-B1F2-E9813F89A39D</gtr:id><gtr:title>High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e65a09bf1b4b055fea41568ad89eb1de"><gtr:id>e65a09bf1b4b055fea41568ad89eb1de</gtr:id><gtr:otherNames>Ge X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5460e999145753.07514853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5C54854-E5C1-44CB-BBB9-FCA3912D78AA</gtr:id><gtr:title>Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bc703f57d1695f3c7bec8e79c7a5470"><gtr:id>4bc703f57d1695f3c7bec8e79c7a5470</gtr:id><gtr:otherNames>Garner CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>5675defa29585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C4E3F18-0E72-4B45-AC5A-B1BB2E8502E1</gtr:id><gtr:title>Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1e16f18e35b8fa3a58302c07c4ea19"><gtr:id>8d1e16f18e35b8fa3a58302c07c4ea19</gtr:id><gtr:otherNames>Cross MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5450d272b44153.01431055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D79CC38D-974E-4850-BBCA-C32C2D46E14D</gtr:id><gtr:title>Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45fedb8ee1637fead70c220f52216105"><gtr:id>45fedb8ee1637fead70c220f52216105</gtr:id><gtr:otherNames>Wing K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>545219a2256f90.58808848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9402E58C-63F0-4FED-9211-D0A1B5594A2D</gtr:id><gtr:title>Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddac4a30749e7a15a7488cd47d44e8e3"><gtr:id>ddac4a30749e7a15a7488cd47d44e8e3</gtr:id><gtr:otherNames>Siddiqui MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn><gtr:outcomeId>598c1d9e8537a8.08561231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>140FFFFB-3AF3-4977-B9AC-946741E570D3</gtr:id><gtr:title>No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2d9fa1a88f103697110ef54a94e06f0"><gtr:id>a2d9fa1a88f103697110ef54a94e06f0</gtr:id><gtr:otherNames>Faulkner L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>585d3613c4a495.49998631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C84F4270-437D-4BD6-A01C-2CE00A56EA0D</gtr:id><gtr:title>Human leukocyte antigen and idiosyncratic adverse drug reactions.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18b81367b9cdf73b016574a36a182dee"><gtr:id>18b81367b9cdf73b016574a36a182dee</gtr:id><gtr:otherNames>Usui T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1347-4367</gtr:issn><gtr:outcomeId>58c7bad48b8957.11821691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>721DA909-2610-48D3-9199-4C5B00384E9A</gtr:id><gtr:title>A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a9df9edd1adbfbf4cf2232aa5fa2dba"><gtr:id>3a9df9edd1adbfbf4cf2232aa5fa2dba</gtr:id><gtr:otherNames>R?disch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>5452189306dd93.56040304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A5FE447-5636-4973-B832-536B09ACBC80</gtr:id><gtr:title>Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bbadd0f352f6fdf78a7060d96e4a3df"><gtr:id>1bbadd0f352f6fdf78a7060d96e4a3df</gtr:id><gtr:otherNames>Zain SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>55dc225768e891.50056959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3C2348D-5DE2-4379-A5F3-1FB6CBC61877</gtr:id><gtr:title>Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f098469dc1dbb18dc75ff4bb9372c1b"><gtr:id>7f098469dc1dbb18dc75ff4bb9372c1b</gtr:id><gtr:otherNames>Goldring C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a2fd37f2096c2.18058052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49F4396C-6841-4BBB-8685-A437DE1E9C78</gtr:id><gtr:title>Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dc4a9ecc43f4532e806a4d1b58a9c81"><gtr:id>3dc4a9ecc43f4532e806a4d1b58a9c81</gtr:id><gtr:otherNames>Manolio TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>5a01b6bd960706.04745033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77885EB8-5C8F-461E-94EF-4AA61DDB6299</gtr:id><gtr:title>CSF1 Restores Innate Immunity After Liver Injury in Mice and&amp;nbsp;Serum Levels Indicate Outcomes of Patients With Acute&amp;nbsp;Liver Failure.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6975485eab4a6d409d81908dfcbf80e2"><gtr:id>6975485eab4a6d409d81908dfcbf80e2</gtr:id><gtr:otherNames>Stutchfield BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56cc37cfe5c4f9.76571300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A98D105-0B63-49A0-97D9-5E6E98E79CDD</gtr:id><gtr:title>Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies.</gtr:title><gtr:parentPublicationTitle>The lancet. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0657e0f67428a9fd42aaeab3b2c965da"><gtr:id>0657e0f67428a9fd42aaeab3b2c965da</gtr:id><gtr:otherNames>Dear JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a14222acc3133.50883212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9C8A750-406C-4648-A786-058692832A5A</gtr:id><gtr:title>Oral anticoagulation: a critique of recent advances and controversies.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>54f6d14fa90e37.10204986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35A71FAB-11DA-40B6-9BC2-5F0363B0134B</gtr:id><gtr:title>Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/251e8f80dc64f3415ad91ed03022c666"><gtr:id>251e8f80dc64f3415ad91ed03022c666</gtr:id><gtr:otherNames>Plumpton CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5577e0e1b6dd63.30628310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C568401D-906D-46FF-BE7A-14207F492CB5</gtr:id><gtr:title>Serum mannose-binding lectin concentration, but not genotype, is associated with Clostridium difficile infection recurrence: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/457947f364d47f74402a3480a442e478"><gtr:id>457947f364d47f74402a3480a442e478</gtr:id><gtr:otherNames>Swale A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>545213c9469836.52779358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>543570BA-4AAB-4C0F-9599-0943B2C2414A</gtr:id><gtr:title>A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/025466a6f52378a6cb32de7d945b59cf"><gtr:id>025466a6f52378a6cb32de7d945b59cf</gtr:id><gtr:otherNames>Speed D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>54521c735c4e94.54220265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4E476AA-4086-4216-974D-13ED9EBD2B0A</gtr:id><gtr:title>Mass Spectrometric and Functional Aspects of Drug-Protein Conjugation.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ea2afe006676f0dfecef58ed9d73a27"><gtr:id>7ea2afe006676f0dfecef58ed9d73a27</gtr:id><gtr:otherNames>Tailor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>585d360dc06260.75307493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AADBE58-A313-4E58-9D0D-A4C11E237F16</gtr:id><gtr:title>Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b2e606c7abd26ebb7b86026fa391727"><gtr:id>8b2e606c7abd26ebb7b86026fa391727</gtr:id><gtr:otherNames>Thompson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>59ca0bbc5819e5.31749897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C831D96-467D-4551-A8D0-9644EBF6AE52</gtr:id><gtr:title>Identification of Organ-Enriched Protein Biomarkers of Acute Liver Injury by Targeted Quantitative Proteomics of Blood in Acetaminophen- and Carbon-Tetrachloride-Treated Mouse Models and Acetaminophen Overdose Patients.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b055cfb3d54d8a03276c5e255bd3c26e"><gtr:id>b055cfb3d54d8a03276c5e255bd3c26e</gtr:id><gtr:otherNames>Qin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>57c835e6bccb12.49869485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FC6FA04-651A-45AD-913D-9F7C50045815</gtr:id><gtr:title>Definition of the Nature and Hapten Threshold of the ?-Lactam Antigen Required for T Cell Activation In Vitro and in Patients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aa79778998f27.85622100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B54FDE8F-BBAD-4D52-BD0F-8656370ABB02</gtr:id><gtr:title>Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/457947f364d47f74402a3480a442e478"><gtr:id>457947f364d47f74402a3480a442e478</gtr:id><gtr:otherNames>Swale A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5452133dc56533.78427640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B8B2402-E460-4BC3-89DF-5D7ED2747100</gtr:id><gtr:title>Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/546e312af2dfee812ff563e099e74bd5"><gtr:id>546e312af2dfee812ff563e099e74bd5</gtr:id><gtr:otherNames>Bracken LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5875dd259fbfb7.47515263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76CEE290-1027-4A30-B5E9-E4E8B2466646</gtr:id><gtr:title>The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death.</gtr:title><gtr:parentPublicationTitle>Toxicology in vitro : an international journal published in association with BIBRA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/060ff5887c8f518c90aea1e8d2d518b1"><gtr:id>060ff5887c8f518c90aea1e8d2d518b1</gtr:id><gtr:otherNames>Kamalian L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-2333</gtr:issn><gtr:outcomeId>56b9b057ded0b6.52713186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBB910CE-0F6E-4E63-B706-1A04860BCE99</gtr:id><gtr:title>Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733c748369e0b187e9271725febc9547"><gtr:id>733c748369e0b187e9271725febc9547</gtr:id><gtr:otherNames>Hawcutt DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5ab22d3ac66856.06631975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17C982EF-944B-4B8B-9D4F-DED0178E7910</gtr:id><gtr:title>ADRIC: Adverse Drug Reactions In Children - a programme of research using mixed methods</gtr:title><gtr:parentPublicationTitle>Programme Grants for Applied Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffe43d74759bfd70a07f13823b4b3bb8"><gtr:id>ffe43d74759bfd70a07f13823b4b3bb8</gtr:id><gtr:otherNames>Smyth R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>57079b2fc74520.80499821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60D53F57-6F0E-4353-A5D3-9D1E700BAAC4</gtr:id><gtr:title>Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1b2121f46ca70f5cebcc8714b61001c"><gtr:id>e1b2121f46ca70f5cebcc8714b61001c</gtr:id><gtr:otherNames>Powell G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>55bf716e621582.45808420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0771724B-EB14-42B5-A15F-07FC7B74BC4B</gtr:id><gtr:title>An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c872ff41113538ab773e310298450ec"><gtr:id>2c872ff41113538ab773e310298450ec</gtr:id><gtr:otherNames>Martin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>59fc6c22d9ad12.49472142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>502FDFBB-D524-4010-951C-7F20FDFA021F</gtr:id><gtr:title>Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f2460e22e02f843ac20e5dbf3ea66b1"><gtr:id>9f2460e22e02f843ac20e5dbf3ea66b1</gtr:id><gtr:otherNames>Thaventhiran T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>doi_55f9849846526189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02EFC7AF-0060-4834-AED6-11F0B1D939F8</gtr:id><gtr:title>Genome-wide association study of warfarin maintenance dose in a Brazilian sample.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79ea0d5b40c0d9838c837750e8e9f53e"><gtr:id>79ea0d5b40c0d9838c837750e8e9f53e</gtr:id><gtr:otherNames>Parra EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>55d584d83af4b1.02588149</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>288B0EE0-13A1-43E5-A443-4AA071A5B649</gtr:id><gtr:title>Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>doi_55f9869869d86c23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83DE10C9-2247-4E90-A200-8BA58ED27B4F</gtr:id><gtr:title>Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/040b7205eaa6d00f1c608aa364140f9f"><gtr:id>040b7205eaa6d00f1c608aa364140f9f</gtr:id><gtr:otherNames>Weemhoff JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>585d3a246df238.58941539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE7970F7-7A8A-4ABA-981B-481D651F1AEC</gtr:id><gtr:title>High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d16e13f6f5171d95fe5e96f95f3a32c"><gtr:id>7d16e13f6f5171d95fe5e96f95f3a32c</gtr:id><gtr:otherNames>Palmblad K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>56d566288b3505.21427333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B89F497-39EE-4F1D-9D2C-80149B5F6919</gtr:id><gtr:title>Immunological Mechanisms of Drug Hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b7b1dadfe0840b56df4eb942edf8fc5"><gtr:id>9b7b1dadfe0840b56df4eb942edf8fc5</gtr:id><gtr:otherNames>Meng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>58c7bad5f12b67.26804936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3874FC12-3D6E-4439-BAF9-BEA51A45D525</gtr:id><gtr:title>GATM gene variants and statin myopathy risk.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>54006763402196.90151153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1105005-8878-489F-ABC0-E1E3193DE44F</gtr:id><gtr:title>HLA restriction of carbamazepine-specific T-Cell clones from an HLA-A*31:01-positive hypersensitive patient.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44047f3f2103c7efda9f3589ed5589c3"><gtr:id>44047f3f2103c7efda9f3589ed5589c3</gtr:id><gtr:otherNames>Lichtenfels M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>54521893660137.27271947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>724AFB4F-1209-4831-A667-47DC483CAC8C</gtr:id><gtr:title>Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b730eed49605806c487d7cf4dae71450"><gtr:id>b730eed49605806c487d7cf4dae71450</gtr:id><gtr:otherNames>Yip VLM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>592fe026b91644.99926185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>332361E3-B023-470F-942F-4E74103F4E1C</gtr:id><gtr:title>Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.</gtr:title><gtr:parentPublicationTitle>Clinical reviews in allergy &amp; immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1080-0549</gtr:issn><gtr:outcomeId>545217cbc9d843.68148575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E54CCB4E-5B23-4373-828E-5350E245AE8E</gtr:id><gtr:title>HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3bfa3b7807d59b84b48dfd2a1228e74"><gtr:id>e3bfa3b7807d59b84b48dfd2a1228e74</gtr:id><gtr:otherNames>Ogese MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>5675e1fd3b299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>038F7AD5-0767-4667-B22F-393B8C8BA061</gtr:id><gtr:title>Promiscuous T-cell responses to drugs and drug-haptens.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/140863ffe037a0ffc39a6a1b50c0aab7"><gtr:id>140863ffe037a0ffc39a6a1b50c0aab7</gtr:id><gtr:otherNames>Yaseen FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>554b1b25291495.65026960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>552ECFC4-D032-4AB7-9D58-D3E5430CF483</gtr:id><gtr:title>TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a498fb492d65a7f05f7ef7fe081174"><gtr:id>56a498fb492d65a7f05f7ef7fe081174</gtr:id><gtr:otherNames>Thiesen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>5903306c296817.83255372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51DFFB7E-24CB-4E75-A71C-6BFA9855869B</gtr:id><gtr:title>Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e68d61df29e65014773a2a32c496271"><gtr:id>0e68d61df29e65014773a2a32c496271</gtr:id><gtr:otherNames>Farzan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>5950f19c351193.75613241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86A762FF-DE05-4FDD-8BF1-8EA9247F6075</gtr:id><gtr:title>Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/251e8f80dc64f3415ad91ed03022c666"><gtr:id>251e8f80dc64f3415ad91ed03022c666</gtr:id><gtr:otherNames>Plumpton CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>59d22e916f1223.29675146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1530F2BC-3D71-41E5-A398-F11EEBC787BF</gtr:id><gtr:title>Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bded6cec3cbccb32e8a38c14ec7d97ba"><gtr:id>bded6cec3cbccb32e8a38c14ec7d97ba</gtr:id><gtr:otherNames>Sutton PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn><gtr:outcomeId>5aa7977a32ed98.78412737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F0B1D7-5635-4CCF-91FE-E55E184E29CB</gtr:id><gtr:title>Effect of Repeated Daily Dosing with 2,4-Dinitrochlorobenzene on Glutathione Biosynthesis and Nrf2 Activation in Reconstructed Human Epidermis.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e385ed2da17c0f2f16e882d842f1a58"><gtr:id>5e385ed2da17c0f2f16e882d842f1a58</gtr:id><gtr:otherNames>Spriggs S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>58c7bad5b15838.11616760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9BE0ADF-6EA0-4195-9525-CE4282932979</gtr:id><gtr:title>In Vitro Priming of Nai?ve T-cells with p-Phenylenediamine and Bandrowski's Base.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff945c76fcdbc4ec138b38b929320297"><gtr:id>ff945c76fcdbc4ec138b38b929320297</gtr:id><gtr:otherNames>Gibson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>55f950fa6354c5.81154771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55FE70A8-9CAE-4A17-B9FC-D7F48858F1C9</gtr:id><gtr:title>Pharmacogenetics of antiepileptic drug-induced hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bf0fabd1f4ebb3c405539c0454ec891"><gtr:id>7bf0fabd1f4ebb3c405539c0454ec891</gtr:id><gtr:otherNames>Bloch KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>545215e4a6e8c8.86830792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82447B39-13F7-40F6-94CE-CC79B0B574C3</gtr:id><gtr:title>Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug metabolism &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/257900edc4f811b1940f71ebb456c735"><gtr:id>257900edc4f811b1940f71ebb456c735</gtr:id><gtr:otherNames>Sullivan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-5255</gtr:issn><gtr:outcomeId>56d565bd4758a6.02297819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4D0A467-33C8-496F-9F9E-A807A8C00E59</gtr:id><gtr:title>Prescribing in liver disease</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>570617bcafcfe0.52387129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9120D5F7-6607-43F2-8B17-1BB7EAB48C04</gtr:id><gtr:title>The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9233596b05f45b6d2e3bc13b1650d055"><gtr:id>9233596b05f45b6d2e3bc13b1650d055</gtr:id><gtr:otherNames>van Staa TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>54521473214336.43557577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7323713A-2196-42CB-9B76-109CB09A2273</gtr:id><gtr:title>Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ac29650cbc6d26e3457f36db9ac85b9"><gtr:id>8ac29650cbc6d26e3457f36db9ac85b9</gtr:id><gtr:otherNames>Konidari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>545217cc2b7bb8.93449820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F976208-147E-4613-9588-16E19699EF4C</gtr:id><gtr:title>Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b33a890e90d14fa3124761f64d50024"><gtr:id>5b33a890e90d14fa3124761f64d50024</gtr:id><gtr:otherNames>Dickens D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c28f4c0ae705.95034528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>324AB628-7274-492C-BAB6-0BC264CFDB19</gtr:id><gtr:title>HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1135539b3674a3fcc0d894286639cded"><gtr:id>1135539b3674a3fcc0d894286639cded</gtr:id><gtr:otherNames>Cornejo Castro EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>54f6d104d317e8.03220006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ABF5D8A-BE55-41D1-8C52-139325589D96</gtr:id><gtr:title>Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011.</gtr:title><gtr:parentPublicationTitle>BMC pharmacology &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bddbcebab2c35ddc738c63f1da257313"><gtr:id>bddbcebab2c35ddc738c63f1da257313</gtr:id><gtr:otherNames>Thomas KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-6511</gtr:issn><gtr:outcomeId>5450d2e99fa268.09618439</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L006758/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>